BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, Cottone M, de Ridder L, Doherty G, Ehehalt R, Esteve M, Katsanos K, Lees CW, Macmahon E, Moreels T, Reinisch W, Tilg H, Tremblay L, Veereman-Wauters G, Viget N, Yazdanpanah Y, Eliakim R, Colombel JF;  European Crohn's and Colitis Organisation (ECCO). Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8:443-468. [PMID: 24613021 DOI: 10.1016/j.crohns.2013.12.013] [Cited by in Crossref: 567] [Cited by in F6Publishing: 456] [Article Influence: 81.0] [Reference Citation Analysis]
Number Citing Articles
1 Guillén MC, Alcover MM, Borruel N, Sulleiro E, Salvador F, Berenguer D, Herrera-de Guise C, Rodríguez V, Moure Z, Sánchez-Montalvà A, Molina I, Fisa R, Riera C. Leishmania infantum asymptomatic infection in inflammatory bowel disease patients under anti-TNF therapy. Heliyon 2020;6:e03940. [PMID: 32420499 DOI: 10.1016/j.heliyon.2020.e03940] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Adams DJ, Nylund CM. Hospitalization for Varicella and Zoster in Children with Inflammatory Bowel Disease. J Pediatr. 2016;171:140-145. [PMID: 26826886 DOI: 10.1016/j.jpeds.2015.12.072] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
3 Tun GS, Harris A, Lobo AJ. Ulcerative colitis: management in adults, children and young people - concise guidance . Clin Med (Lond) 2017;17:429-33. [PMID: 28974592 DOI: 10.7861/clinmedicine.17-5-429] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
4 Kim JH, Kim JW. Effect of Immunomodulators and Biologic Agents on Malignancy in Patients with Inflammatory Bowel Disease. Korean J Gastroenterol 2017;70:162. [DOI: 10.4166/kjg.2017.70.4.162] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Lim SZ, Chua EW. Revisiting the Role of Thiopurines in Inflammatory Bowel Disease Through Pharmacogenomics and Use of Novel Methods for Therapeutic Drug Monitoring. Front Pharmacol. 2018;9:1107. [PMID: 30349479 DOI: 10.3389/fphar.2018.01107] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
6 Reinisch W, Gecse K, Halfvarson J, Irving PM, Jahnsen J, Peyrin-Biroulet L, Rogler G, Schreiber S, Danese S. Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease. Inflamm Bowel Dis 2021;27:106-22. [PMID: 32634212 DOI: 10.1093/ibd/izaa078] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Gagnière C, Bourrier A, Seksik P, Gornet J, Dewit O, Nancey S, Altwegg R, Abitbol V, Laharie D, Reenaers C, Buisson A, Pariente B, Viennot S, Vuitton L, Stefanescu C, Marteau P, Bouguen G, Cosnes J, Amiot A; the GETAID INFOPRO study group. Risk of serious infection in healthcare workers with inflammatory bowel disease: a case-control study of the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID). Aliment Pharmacol Ther 2018;48:713-22. [DOI: 10.1111/apt.14926] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
8 Sebastian S, Gonzalez HA, Peyrin-Biroulet L. Safety of Drugs During Previous and Current Coronavirus Pandemics: Lessons for Inflammatory Bowel Disease. J Crohns Colitis. 2020;14:1632-1643. [PMID: 32520312 DOI: 10.1093/ecco-jcc/jjaa120] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
9 van der Sloot KWJ, Voskuil MD, Visschedijk MC, Festen EAM, van Dullemen HM, Weersma RK, Alizadeh BZ, van Leer-Buter C, Dijkstra G. Latent cytomegalovirus infection does not influence long-term disease outcomes in inflammatory bowel disease, but is associated with later onset of disease. Scand J Gastroenterol 2020;55:891-6. [PMID: 32633160 DOI: 10.1080/00365521.2020.1786853] [Reference Citation Analysis]
10 Borman ZA, Côté-daigneault J, Colombel J. The risk for opportunistic infections in inflammatory bowel disease with biologics: an update. Expert Review of Gastroenterology & Hepatology 2018;12:1101-8. [DOI: 10.1080/17474124.2018.1530983] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
11 Papa A, Scaldaferri F, Vetrone LM, Neri M, Gasbarrini A, Lopetuso LR. How to Face the Advent of SARS-CoV-2 Vaccination in IBD Patients: Another Task for Gastroenterologists. Vaccines (Basel) 2021;9:248. [PMID: 33808983 DOI: 10.3390/vaccines9030248] [Reference Citation Analysis]
12 Sultan K, Mone A, Durbin L, Khuwaja S, Swaminath A. Review of inflammatory bowel disease and COVID-19. World J Gastroenterol. 2020;26:5534-5542. [PMID: 33088153 DOI: 10.3748/wjg.v26.i37.5534] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
13 Higashiyama M, Sugita A, Koganei K, Wanatabe K, Yokoyama Y, Uchino M, Nagahori M, Naganuma M, Bamba S, Kato S, Takeuchi K, Omori T, Takagi T, Matsumoto S, Nagasaka M, Sagami S, Kitamura K, Katsurada T, Sugimoto K, Takatsu N, Saruta M, Sakurai T, Watanabe K, Nakamura S, Suzuki Y, Hokari R. Management of elderly ulcerative colitis in Japan. J Gastroenterol 2019;54:571-86. [PMID: 31025187 DOI: 10.1007/s00535-019-01580-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
14 Kirchgesner J, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases. Gastroenterology. 2018;155:337-346.e10. [PMID: 29655835 DOI: 10.1053/j.gastro.2018.04.012] [Cited by in Crossref: 194] [Cited by in F6Publishing: 159] [Article Influence: 64.7] [Reference Citation Analysis]
15 Magdziak A, Szlak J, Mróz A, Wieszczy P, Zagórowicz E. A stool test in patients with active ulcerative colitis helps exclude cytomegalovirus disease. Scand J Gastroenterol 2020;55:664-70. [PMID: 32552149 DOI: 10.1080/00365521.2020.1771760] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Ryu JS, Im SH, Kang YK, Kim YS, Chung HJ. Ultra-fast and universal detection of Gram-negative bacteria in complex samples based on colistin derivatives. Biomater Sci 2020;8:2111-9. [PMID: 31967117 DOI: 10.1039/c9bm01926j] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Temtem T, Whitworth J, Zhang J, Bagga B. Cytomegalovirus in pediatric inflammatory bowel disease patients with acute severe colitis. Clin Res Hepatol Gastroenterol 2021;45:101625. [PMID: 33662784 DOI: 10.1016/j.clinre.2021.101625] [Reference Citation Analysis]
18 Wisniewski A, Fléjou JF, Siproudhis L, Abramowitz L, Svrcek M, Beaugerie L. Anal Neoplasia in Inflammatory Bowel Disease: Classification Proposal, Epidemiology, Carcinogenesis, and Risk Management Perspectives. J Crohns Colitis 2017;11:1011-8. [PMID: 28379306 DOI: 10.1093/ecco-jcc/jjx035] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
19 Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, Makharia GK, Pisespongsa P, Chen MH, Ran ZH, Ye BD, Park DI, Ling KL, Ong D, Ahuja V, Goh KL, Sollano J, Lim WC, Leung WK, Ali RAR, Wu DC, Ong E, Mustaffa N, Limsrivilai J, Hisamatsu T, Yang SK, Ouyang Q, Geary R, De Silva JH, Rerknimitr R, Simadibrata M, Abdullah M, Leong RW; Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn’s and Colitis. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. Intest Res 2019;17:285-310. [PMID: 31146509 DOI: 10.5217/ir.2019.00026] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 15.0] [Reference Citation Analysis]
20 Baranowska-Nowak M, IwaŃczak B, Szczepanik M, Banasiuk M, DembiŃski Ł, Karolewska-Bochenek K, Dziekiewicz M, Radzikowski A, Banaszkiewicz A. Immune response to hepatitis B vaccination in pediatric patients with inflammatory bowel disease. Cent Eur J Immunol 2020;45:144-50. [PMID: 33456324 DOI: 10.5114/ceji.2020.97902] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Gawronska A, Banasiuk M, Lachowicz D, Pituch H, Albrecht P, Banaszkiewicz A. Metronidazole or Rifaximin for Treatment of Clostridium difficile in Pediatric Patients with Inflammatory Bowel Disease: A Randomized Clinical Trial. Inflammatory Bowel Diseases 2017;23:2209-14. [DOI: 10.1097/mib.0000000000001249] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
22 Gordon J, Ramaswami A, Beuttler M, Jossen J, Pittman N, Lai J, Dunkin D, Benkov K, Dubinsky M. EBV Status and Thiopurine Use in Pediatric IBD. J Pediatr Gastroenterol Nutr 2016;62:711-4. [PMID: 26655944 DOI: 10.1097/MPG.0000000000001077] [Cited by in Crossref: 22] [Cited by in F6Publishing: 6] [Article Influence: 7.3] [Reference Citation Analysis]
23 Greveson K, Shepherd T, Mulligan JP, Hamilton M, Woodward S, Norton C, Murray C. Travel health and pretravel preparation in the patient with inflammatory bowel disease. Frontline Gastroenterol 2016;7:60-5. [PMID: 28839835 DOI: 10.1136/flgastro-2014-100548] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
24 Papamichael K, Mantzaris GJ, Peyrin-Biroulet L. A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease. Expert Opin Drug Saf 2016;15:493-501. [PMID: 26799429 DOI: 10.1517/14740338.2016.1145653] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
25 Nimmons D, Limdi JK. Elderly patients and inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2016;7:51-65. [PMID: 26855812 DOI: 10.4292/wjgpt.v7.i1.51] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 21] [Article Influence: 6.2] [Reference Citation Analysis]
26 Jentzer A, Veyrard P, Roblin X, Saint-Sardos P, Rochereau N, Paul S, Bourlet T, Pozzetto B, Pillet S. Cytomegalovirus and Inflammatory Bowel Diseases (IBD) with a Special Focus on the Link with Ulcerative Colitis (UC). Microorganisms 2020;8:E1078. [PMID: 32698383 DOI: 10.3390/microorganisms8071078] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
27 Dipasquale V, Romano C. Vaccination strategies in pediatric inflammatory bowel disease. Vaccine 2017;35:6070-5. [DOI: 10.1016/j.vaccine.2017.09.031] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
28 Shah R, Ho EY, Kramer JR, Richardson P, Sansgiry S, El-Serag HB, Hou JK. Hepatitis B Virus Screening and Reactivation in a National VA Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Antagonists. Dig Dis Sci. 2018;63:1551-1557. [PMID: 29663266 DOI: 10.1007/s10620-018-5042-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
29 Clarke WT, Amin SS, Papamichael K, Feuerstein JD, Cheifetz AS. Patients with core antibody positive and surface antigen negative Hepatitis B (anti-HBc+, HBsAg−) on anti-TNF therapy have a low rate of reactivation. Clinical Immunology 2018;191:59-62. [DOI: 10.1016/j.clim.2018.03.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
30 Jouyban K, Mazaher Haji Agha E, Hemmati S, Martinez F, Kuentz M, Jouyban A. Solubility of 5-aminosalicylic acid in N-methyl-2-pyrrolidone + water mixtures at various temperatures. Journal of Molecular Liquids 2020;310:113143. [DOI: 10.1016/j.molliq.2020.113143] [Cited by in Crossref: 14] [Cited by in F6Publishing: 1] [Article Influence: 14.0] [Reference Citation Analysis]
31 Khan N, Shah Y, Trivedi C, Lewis JD. Safety of herpes zoster vaccination among inflammatory bowel disease patients being treated with anti-TNF medications. Aliment Pharmacol Ther 2017;46:668-72. [PMID: 28805309 DOI: 10.1111/apt.14257] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
32 Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Nathwani R, Taha MS, Limdi JK. First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World J Gastroenterol 2020;26:6710-69. [PMID: 33268959 DOI: 10.3748/wjg.v26.i43.6710] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
33 Lopes S, Andrade P, Conde S, Liberal R, Dias CC, Fernandes S, Pinheiro J, Simões JS, Carneiro F, Magro F, Macedo G. Looking into Enteric Virome in Patients with IBD: Defining Guilty or Innocence? Inflammatory Bowel Diseases 2017;23:1278-84. [DOI: 10.1097/mib.0000000000001167] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
34 Bryant R, Sandborn W, Travis S. Introducing Vedolizumab to Clinical Practice: Who, When, and How? Journal of Crohn's and Colitis 2015;9:356-66. [DOI: 10.1093/ecco-jcc/jjv033] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 6.5] [Reference Citation Analysis]
35 Ribaldone DG, Astegiano M, Actis GC, Pellicano R. Management of inflammatory bowel disease during COVID-19 pandemic. Minerva Gastroenterol Dietol 2020;66:184-6. [PMID: 32327626 DOI: 10.23736/S1121-421X.20.02707-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
36 Kucharzik T, Dignass AU, Atreya R, Bokemeyer B, Esters P, Herrlinger K, Kannengießer K, Kienle P, Langhorst J, Lügering A, Schreiber S, Stallmach A, Stein J, Sturm A, Teich N, Siegmund B; Collaborators:. Aktualisierte S3-Leitlinie Colitis ulcerosa – Living Guideline. Z Gastroenterol 2020;58:e241-326. [PMID: 33260237 DOI: 10.1055/a-1296-3444] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
37 Benchimol EI, Tse F, Carroll MW, deBruyn JC, McNeil SA, Pham-Huy A, Seow CH, Barrett LL, Bessissow T, Carman N, Melmed GY, Vanderkooi OG, Marshall JK, Jones JL. Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)-Part 1: Live Vaccines. Gastroenterology 2021;161:669-680.e0. [PMID: 33617891 DOI: 10.1053/j.gastro.2020.12.079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
38 Kredel LI, Mundt P, van Riesen L, Jöhrens K, Hofmann J, Loddenkemper C, Siegmund B, Preiß JC. Accuracy of diagnostic tests and a new algorithm for diagnosing cytomegalovirus colitis in inflammatory bowel diseases: a diagnostic study. Int J Colorectal Dis 2019;34:229-37. [DOI: 10.1007/s00384-018-3170-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
39 Umar S, Clarke K, Bilimoria F, Bilal M, Singh S, Silverman J. Diagnostic yield from colon biopsies in patients with inflammatory bowel disease and suspected cytomegalovirus infection: is it worth it? Ann Gastroenterol 2017;30:429-32. [PMID: 28655979 DOI: 10.20524/aog.2017.0153] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
40 Hirschmann S, Neurath MF. Top-down approach to biological therapy of Crohn's disease. Expert Opin Biol Ther 2017;17:285-93. [PMID: 28132526 DOI: 10.1080/14712598.2017.1287170] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
41 Rowan C, Judge C, Cannon MD, Cullen G, Mulcahy HE, Ryan E, De Gascun CF, Doherty GA. Severe Symptomatic Primary CMV Infection in Inflammatory Bowel Disease Patients with Low Population Seroprevalence. Gastroenterol Res Pract 2018;2018:1029401. [PMID: 30050572 DOI: 10.1155/2018/1029401] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
42 Shimada T, Nagata N, Okahara K, Joya A, Hayashida T, Oka S, Sakurai T, Akiyama J, Uemura N, Gatanaga H. PCR detection of human herpesviruses in colonic mucosa of individuals with inflammatory bowel disease: Comparison with individuals with immunocompetency and HIV infection. PLoS One 2017;12:e0184699. [PMID: 28902907 DOI: 10.1371/journal.pone.0184699] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
43 Seo H, Chang K, Lee S, Song E, Kim G, Seo M, Lee H, Hwang S, Yang D, Kim K, Ye BD, Byeon J, Myung S, Yang S, Park SH. Long-term outcomes of infliximab treatment and predictors of response in 195 patients with ulcerative colitis: a hospital-based cohort study from Korea. Scandinavian Journal of Gastroenterology 2017;52:857-63. [DOI: 10.1080/00365521.2017.1323229] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
44 Zhou JQ, Zeng L, Zhang Q, Wu XY, Zhang ML, Jing XT, Wang YF, Gan HT. Clinical features of Epstein-Barr virus in the intestinal mucosa and blood of patients with inflammatory bowel disease. Saudi J Gastroenterol 2020. [PMID: 33078719 DOI: 10.4103/sjg.SJG_30_20] [Reference Citation Analysis]
45 Akyuz F, Cavus B, Iliaz R, Soyer OM, Ormeci A, Evirgen S, Onder S, Koksalan K, Keskin M, Karaca C, Demir K, Gulluoglu M, Cagatay T, Besisik F, Kaymakoglu S. Inflammatory bowel disease and mycobacteria: how much can we trust isoniazid prophylaxis during antitumor necrosis factor therapy? Eur J Gastroenterol Hepatol. 2019;31:777-780. [PMID: 30964811 DOI: 10.1097/meg.0000000000001403] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
46 Egan C, Doherty GA. Why do we need to improve monitoring of patients with inflammatory bowel disease (IBD) on biologic treatment? Expert Opinion on Biological Therapy 2019;19:907-18. [DOI: 10.1080/14712598.2019.1615050] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
47 Hasani Z, Aghdaei HA, Balaii H, Azimirad M, Mirsamadi ES, Mirjalali H, Zali MR. The first study on opportunistic intestinal microsporidiosis in IBD patients receiving immunosuppressive medications in Iran. Epidemiol Infect. 2017;145:2095-2099. [PMID: 28502260 DOI: 10.1017/s0950268817000954] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
48 Spencer NJ, Fryer AA, Farmer AD, Duff CJ. Blood test monitoring of immunomodulatory therapy in inflammatory disease. BMJ. [DOI: 10.1136/bmj.n159] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Coskun M, Steenholdt C, de Boer NK, Nielsen OH. Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease. Clin Pharmacokinet. 2016;55:257-274. [PMID: 26255287 DOI: 10.1007/s40262-015-0316-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
50 Byun JM, Lee CK, Rhee SY, Kim H, Im JP, Park DI, Eun CS, Jung S, Shin JE, Lee K, Cheon JH. Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-α inhibitor. Scandinavian Journal of Gastroenterology 2014;50:312-20. [DOI: 10.3109/00365521.2014.1000960] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 5.3] [Reference Citation Analysis]
51 Tandon P, James P, Cordeiro E, Mallick R, Shukla T, McCurdy JD. Diagnostic Accuracy of Blood-Based Tests and Histopathology for Cytomegalovirus Reactivation in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Inflamm Bowel Dis 2017;23:551-60. [PMID: 28296820 DOI: 10.1097/MIB.0000000000001073] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 5.3] [Reference Citation Analysis]
52 Hawthorne TZ, Shellien R, Chambers L, Devereux G. CMV pneumonitis in a patient with Crohn's disease taking azathioprine. BMJ Case Rep 2021;14:e241256. [PMID: 33893128 DOI: 10.1136/bcr-2020-241256] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Yamamoto-furusho J, Gutiérrez-grobe Y, López-gómez J, Bosques-padilla F, Rocha-ramírez J. The Mexican consensus on the diagnosis and treatment of ulcerative colitis. Revista de Gastroenterología de México (English Edition) 2018;83:144-67. [DOI: 10.1016/j.rgmxen.2018.04.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Kumar A, Quraishi MN, Segal JP, Raine T, Brookes MJ. COVID-19 vaccinations in patients with inflammatory bowel disease. Lancet Gastroenterol Hepatol 2020;5:965-6. [PMID: 32971020 DOI: 10.1016/S2468-1253(20)30295-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
55 Brenner EJ, Ungaro RC, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, Ng SC, Rahier J-F, Reinisch W, Ruemmele FM, Steinwurz F, Underwood FE, Zhang X, Colombel J-F, Kappelman MD. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. Gastroenterology. 2020;159:481-491.e483. [PMID: 32425234 DOI: 10.1053/j.gastro.2020.05.032] [Cited by in Crossref: 265] [Cited by in F6Publishing: 230] [Article Influence: 265.0] [Reference Citation Analysis]
56 Winthrop KL, Loftus EV, Baumgart DC, Reinisch W, Nduaka CI, Lawendy N, Chan G, Mundayat R, Friedman GS, Salese L, Thorpe AJ, Su C. Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme. J Crohns Colitis 2021;15:914-29. [PMID: 33245746 DOI: 10.1093/ecco-jcc/jjaa233] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
57 Pouillon L, Van Stappen J, Bossuyt P, Danese S, Peyrin-biroulet L. Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis? Best Practice & Research Clinical Gastroenterology 2018;32-33:17-25. [DOI: 10.1016/j.bpg.2018.05.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
58 Day AS, Gulati AS, Patel N, Boyle B, Park KT, Saeed SA. The Role of Combination Therapy in Pediatric Inflammatory Bowel Disease: A Clinical Report from the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;66:361-8. [PMID: 29210919 DOI: 10.1097/MPG.0000000000001850] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
59 Seitel T, Cagol L, Prelog M, Frivolt K, Krahl A, Trenkel S, Speth F, Mayer B, Almanzar G, Koletzko S, Debatin KM, Mertens T, Posovszky C. Varicella-zoster-virus vaccination of immunosuppressed children with inflammatory bowel disease or autoimmune hepatitis: A prospective observational study. Vaccine 2020;38:8024-31. [PMID: 33160754 DOI: 10.1016/j.vaccine.2020.10.028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
60 Ungaro F, Massimino L, D'Alessio S, Danese S. The gut virome in inflammatory bowel disease pathogenesis: From metagenomics to novel therapeutic approaches. United European Gastroenterol J 2019;7:999-1007. [PMID: 31662858 DOI: 10.1177/2050640619876787] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
61 Song DJ, Tong JL, Peng JC, Cai CW, Xu XT, Zhu MM, Ran ZH, Zheng Q. Tuberculosis screening using IGRA and chest computed tomography in patients with inflammatory bowel disease: A retrospective study. J Dig Dis 2017;18:23-30. [PMID: 28009090 DOI: 10.1111/1751-2980.12437] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
62 Yerushalmy-Feler A, Kern-Isaacs S, Cohen S. CMV Infection in Pediatric IBD. Curr Gastroenterol Rep 2018;20:13. [PMID: 29594760 DOI: 10.1007/s11894-018-0617-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
63 Pham HV, Hasan I, Udaltsova N, Pham K, Abramson O, Armstrong MA, Postlethwaite D, Li D. Rates and Predictors of Vaccinations Among Inflammatory Bowel Disease Patients Receiving Anti-Tumor Necrosis Factor Agents. Dig Dis Sci 2018;63:209-17. [PMID: 28836068 DOI: 10.1007/s10620-017-4716-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
64 Angelino G, De Angelis P, Faraci S, Rea F, Romeo EF, Torroni F, Tambucci R, Claps A, Francalanci P, Chiriaco M, Di Matteo G, Cancrini C, Palma P, D'argenio P, Dall'oglio L, Rossi P, Finocchi A. Inflammatory bowel disease in chronic granulomatous disease: An emerging problem over a twenty years' experience. Pediatr Allergy Immunol 2017;28:801-9. [DOI: 10.1111/pai.12814] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
65 Vajravelu RK, Osterman MT, Aberra FN, Roy JA, Lichtenstein GR, Mamtani R, Goldberg DS, Lewis JD, Scott FI. Indeterminate QuantiFERON-TB Gold Increases Likelihood of Inflammatory Bowel Disease Treatment Delay and Hospitalization. Inflamm Bowel Dis 2017;24:217-26. [PMID: 29272482 DOI: 10.1093/ibd/izx019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
66 Andersen NN, Jess T. Risk of infections associated with biological treatment in inflammatory bowel disease. World J Gastroenterol. 2014;20:16014-16019. [PMID: 25473153 DOI: 10.3748/wjg.v20.i43.16014] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]
67 Mériglier E, Coudroy R, Agius G. Hépatite fulminante fatale à virus de la varicelle-zona chez une patiente porteuse d’une maladie de Crohn traitée par anti-TNF alpha. Médecine et Maladies Infectieuses 2014;44:484-6. [DOI: 10.1016/j.medmal.2014.09.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
68 Macaluso FS, Renna S, Orlando A, Cottone M. The biologics of ulcerative colitis. Expert Opinion on Biological Therapy 2016;17:175-84. [DOI: 10.1080/14712598.2017.1271871] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
69 Dahmus J, Rosario M, Clarke K. Risk of Lymphoma Associated with Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: Implications for Therapy. Clin Exp Gastroenterol 2020;13:339-50. [PMID: 32982364 DOI: 10.2147/CEG.S237646] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
70 Park JR, Pfeil SA. Primary Care of the Patient with Inflammatory Bowel Disease. Med Clin North Am 2015;99:969-87. [PMID: 26320042 DOI: 10.1016/j.mcna.2015.05.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
71 Beswick L, Ye B, van Langenberg DR. Toward an Algorithm for the Diagnosis and Management of CMV in Patients with Colitis: . Inflammatory Bowel Diseases 2016;22:2966-76. [DOI: 10.1097/mib.0000000000000958] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 4.6] [Reference Citation Analysis]
72 Li W, Zhang Z, Jiang X. Once daily vs multiple daily mesalamine therapy for mild to moderate ulcerative colitis: a meta-analysis. Colorectal Dis 2016;18:O214-23. [DOI: 10.1111/codi.13393] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
73 Banaszkiewicz A, Gawronska A, Klincewicz B, Kofla-Dłubacz A, Grzybowska-Chlebowczyk U, Toporowska-Kowalska E, Malecka I, Stryczynska-Kazubska J, Feleszko W, Lazowska-Przeorek I, Karolewska-Bochenek K, Walkowiak J, Slusarczyk J, Radzikowski A, Demkow U, Albrecht P. Immunogenicity of Pertussis Booster Vaccination in Children and Adolescents with Inflammatory Bowel Disease: A Controlled Study. Inflamm Bowel Dis 2017;23:847-52. [PMID: 28394806 DOI: 10.1097/MIB.0000000000001076] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
74 Kopylov U, Ron Y, Avni-Biron I, Koslowsky B, Waterman M, Daher S, Ungar B, Yanai H, Maharshak N, Ben-Bassat O. Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World Experience. Inflamm Bowel Dis. 2017;23:404-408. [PMID: 28178003 DOI: 10.1097/mib.0000000000001039] [Cited by in Crossref: 57] [Cited by in F6Publishing: 25] [Article Influence: 19.0] [Reference Citation Analysis]
75 Regueiro MD, Mcanallen SE, Greer JB, Perkins SE, Ramalingam S, Szigethy E. The Inflammatory Bowel Disease Specialty Medical Home: A New Model of Patient-centered Care. Inflammatory Bowel Diseases 2016;22:1971-80. [DOI: 10.1097/mib.0000000000000819] [Cited by in Crossref: 44] [Cited by in F6Publishing: 9] [Article Influence: 8.8] [Reference Citation Analysis]
76 deBruyn J, Fonseca K, Ghosh S, Panaccione R, Gasia MF, Ueno A, Kaplan GG, Seow CH, Wrobel I. Immunogenicity of Influenza Vaccine for Patients with Inflammatory Bowel Disease on Maintenance Infliximab Therapy: A Randomized Trial. Inflamm Bowel Dis 2016;22:638-47. [PMID: 26595551 DOI: 10.1097/MIB.0000000000000615] [Cited by in Crossref: 44] [Cited by in F6Publishing: 14] [Article Influence: 8.8] [Reference Citation Analysis]
77 Martinelli M, Giugliano FP, Strisciuglio C, Urbonas V, Serban DE, Banaszkiewicz A, Assa A, Hojsak I, Lerchova T, Navas-López VM, Romano C, Sladek M, Veres G, Aloi M, Kucinskiene R, Miele E. Vaccinations and Immunization Status in Pediatric Inflammatory Bowel Disease: A Multicenter Study From the Pediatric IBD Porto Group of the ESPGHAN. Inflamm Bowel Dis 2020;26:1407-14. [PMID: 31689349 DOI: 10.1093/ibd/izz264] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
78 Quera R, Simian D, Núñez P, Flores L, Figueroa C, Ibáñez P, Kronberg U, Lubascher J, Pizarro G. Are patients with inflammatory bowel disease receiving adequate immunisation? Gastroenterol Hepatol 2021;44:198-205. [PMID: 33131901 DOI: 10.1016/j.gastrohep.2020.06.024] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Doornekamp L, Goetgebuer RL, Schmitz KS, Goeijenbier M, van der Woude CJ, Fouchier R, van Gorp ECM, de Vries AC. High Immunogenicity to Influenza Vaccination in Crohn's Disease Patients Treated with Ustekinumab. Vaccines (Basel). 2020;8. [PMID: 32824111 DOI: 10.3390/vaccines8030455] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 13.0] [Reference Citation Analysis]
80 Ludvigsson JF, Holmgren J, Grip O, Halfvarson J, Askling J, Sachs MC, Olén O. Adult-onset inflammatory bowel disease and rate of serious infections compared to the general population: a nationwide register-based cohort study 2002-2017. Scand J Gastroenterol 2021;:1-11. [PMID: 34369254 DOI: 10.1080/00365521.2021.1924259] [Reference Citation Analysis]
81 Rolling T, Mühlenpfordt M, Addo MM, Cramer JP, Vinnemeier CD. Pre-travel advice at a crossroad: Medical preparedness of travellers to South and Southeast-Asia - The Hamburg Airport Survey. Travel Med Infect Dis 2017;18:41-5. [PMID: 28733254 DOI: 10.1016/j.tmaid.2017.07.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
82 Dart RJ, Irving PM. Optimising use of thiopurines in inflammatory bowel disease. Expert Review of Clinical Immunology 2017;13:877-88. [DOI: 10.1080/1744666x.2017.1351298] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
83 Davis JS, Ferreira D, Paige E, Gedye C, Boyle M. Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. Clin Microbiol Rev 2020;33:e00035-19. [PMID: 32522746 DOI: 10.1128/CMR.00035-19] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 11.0] [Reference Citation Analysis]
84 Siegmund B. Cytomegalovirus infection associated with inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2017;2:369-376. [PMID: 28397701 DOI: 10.1016/s2468-1253(16)30159-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 3.3] [Reference Citation Analysis]
85 Phadke VK, Friedman-Moraco RJ, Quigley BC, Farris AB, Norvell JP. Concomitant herpes simplex virus colitis and hepatitis in a man with ulcerative colitis: Case report and review of the literature. Medicine (Baltimore) 2016;95:e5082. [PMID: 27759636 DOI: 10.1097/MD.0000000000005082] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
86 van Aalst M, Lötsch F, Spijker R, van der Meer JTM, Langendam MW, Goorhuis A, Grobusch MP, de Bree GJ. Incidence of invasive pneumococcal disease in immunocompromised patients: A systematic review and meta-analysis. Travel Med Infect Dis 2018;24:89-100. [PMID: 29860151 DOI: 10.1016/j.tmaid.2018.05.016] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 13.0] [Reference Citation Analysis]
87 Yamamoto-furusho J, Gutiérrez-grobe Y, López-gómez J, Bosques-padilla F, Rocha-ramírez J. Consenso mexicano para el diagnóstico y tratamiento de la colitis ulcerosa crónica idiopática. Revista de Gastroenterología de México 2018;83:144-67. [DOI: 10.1016/j.rgmx.2017.08.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
88 Chang MS, Nguyen MH. Epidemiology of hepatitis B and the role of vaccination. Best Pract Res Clin Gastroenterol 2017;31:239-47. [PMID: 28774405 DOI: 10.1016/j.bpg.2017.05.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
89 Zhou R, Chang Y, Liu J, Chen M, Wang H, Huang M, Liu S, Wang X, Zhao Q. JNK Pathway-Associated Phosphatase/DUSP22 Suppresses CD4+ T-Cell Activation and Th1/Th17-Cell Differentiation and Negatively Correlates with Clinical Activity in Inflammatory Bowel Disease. Front Immunol. 2017;8:781. [PMID: 28725226 DOI: 10.3389/fimmu.2017.00781] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
90 Silva NOE, Brito BBD, Silva FAFD, Santos MLC, Melo FFD. Probiotics in inflammatory bowel disease: Does it work? WJAM 2020;8:54-66. [DOI: 10.13105/wjma.v8.i2.54] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
91 Sharma E, Meade S, D'Errico F, Pavlidis P, Luber R, Zeki S, Hill K, Duff A, O'Hanlon D, Tripoli S, Stanton A, Caracostea A, Honap S, Reynolds R, Anderson S, Ray S, Mawdsley J, Sanderson J, Samaan MA, Irving PM. The effects of COVID-19 on IBD prescribing and service provision in a UK tertiary centre. GastroHep 2020;2:318-26. [PMID: 33362435 DOI: 10.1002/ygh2.433] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
92 Ananthakrishnan AN, Cagan A, Cai T, Gainer VS, Shaw SY, Churchill S, Karlson EW, Murphy SN, Kohane I, Liao KP. Diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases. Aliment Pharmacol Ther 2015;41:1141-8. [PMID: 25864945 DOI: 10.1111/apt.13195] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
93 Bermejo F, Aguas M, Chaparro M, Domènech E, Echarri A, García-Planella E, Guerra I, Gisbert JP, López-Sanromán A; en representación de GETECCU. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of thiopurines in inflammatory bowel disease. Gastroenterol Hepatol 2018;41:205-21. [PMID: 29357999 DOI: 10.1016/j.gastrohep.2017.11.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 5.3] [Reference Citation Analysis]
94 Jauregui-Amezaga A, Vermeire S, Prenen H. Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer. Ann Gastroenterol 2016;29:127-36. [PMID: 27065724 DOI: 10.20524/aog.2016.0004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
95 Bontà J, Zeitz J, Frei P, Biedermann L, Sulz MC, Vavricka SR, Scharl S, Fried M, Rogler G, Scharl M. Cytomegalovirus disease in inflammatory bowel disease: epidemiology and disease characteristics in a large single-centre experience. Eur J Gastroenterol Hepatol 2016;28:1329-34. [PMID: 27482785 DOI: 10.1097/MEG.0000000000000716] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
96 Komoto S, Higashiyama M, Watanabe C, Suzuki Y, Watanabe M, Hibi T, Takebayashi T, Asakura K, Nishiwaki Y, Miura S, Hokari R. Clinical differences between elderly-onset ulcerative colitis and non-elderly-onset ulcerative colitis: A nationwide survey data in Japan. J Gastroenterol Hepatol 2018;33:1839-43. [PMID: 29669163 DOI: 10.1111/jgh.14263] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 4.7] [Reference Citation Analysis]
97 Sousa P, Allez M. Complications of biologics in inflammatory bowel disease. Curr Opin Gastroenterol. 2015;31:296-302. [PMID: 26039721 DOI: 10.1097/mog.0000000000000191] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
98 Hsu CC, Okumura R, Motooka D, Sasaki R, Nakamura S, Iida T, Takeda K. Alleviation of colonic inflammation by Lypd8 in a mouse model of inflammatory bowel disease. Int Immunol 2021;33:359-72. [PMID: 33822948 DOI: 10.1093/intimm/dxab012] [Reference Citation Analysis]
99 Park DI, Hisamatsu T, Chen M, Ng SC, Ooi CJ, Wei SC, Banerjee R, Hilmi IN, Jeen YT, Han DS, Kim HJ, Ran Z, Wu K, Qian J, Hu PJ, Matsuoka K, Andoh A, Suzuki Y, Sugano K, Watanabe M, Hibi T, Puri AS, Yang SK. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management. Intest Res 2018;16:17-25. [PMID: 29422794 DOI: 10.5217/ir.2018.16.1.17] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
100 Abreu C, Afonso J, Camila Dias C, Ruas R, Sarmento A, Magro F. Serial Tuberculosis Screening in Inflammatory Bowel Disease Patients Receiving Anti-TNFα Therapy. J Crohns Colitis 2017;11:1223-9. [PMID: 28605520 DOI: 10.1093/ecco-jcc/jjx080] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
101 Wang S, Dou Y, Yang H, Ni A, Zhang R, Qian J. Alteration of glucocorticoid receptors and exacerbation of inflammation during lytic cytomegalovirus infection in THP-1 cells. FEBS Open Bio 2017;7:1924-31. [PMID: 29226079 DOI: 10.1002/2211-5463.12334] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
102 Bye WA, Sparrow MP, Connor SJ, Andrews JM, Ellard K, Ng W, Hume G, Antoniades S, Walsh AJ. The need for better preventative strategies for inflammatory bowel disease patients at risk of herpes zoster virus: Herpes zoster vaccine in IBD patients. Intern Med J 2017;47:1263-9. [DOI: 10.1111/imj.13488] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
103 Waszczuk E, Waszczuk KM, Mulak A, Paradowski L. Inadequate seroprotection against hepatitis B virus and one detected case of hepatitis C virus infection among patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2016;28:628-632. [PMID: 26904976 DOI: 10.1097/meg.0000000000000613] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
104 Hindryckx P, Jairath V, D'Haens G. Acute severe ulcerative colitis: from pathophysiology to clinical management. Nat Rev Gastroenterol Hepatol. 2016;13:654-664. [PMID: 27580687 DOI: 10.1038/nrgastro.2016.116] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 11.2] [Reference Citation Analysis]
105 Kopylov U, Papamichael K, Katsanos K, Waterman M, Bar-Gil Shitrit A, Boysen T, Portela F, Peixoto A, Szilagyi A, Silva M, Maconi G, Har-Noy O, Bossuyt P, Mantzaris G, Barreiro de Acosta M, Chaparro M, Christodoulou DK, Eliakim R, Rahier JF, Magro F, Drobne D, Ferrante M, Sonnenberg E, Siegmund B, Muls V, Thurm T, Yanai H, Dotan I, Raine T, Levin A, Israeli E, Ghalim F, Carbonnel F, Vermeire S, Ben-Horin S, Roblin X. Impact of Infliximab and Cyclosporine on the Risk of Colectomy in Hospitalized Patients with Ulcerative Colitis Complicated by Cytomegalovirus-A Multicenter Retrospective Study. Inflamm Bowel Dis 2017;23:1605-13. [PMID: 28590343 DOI: 10.1097/MIB.0000000000001160] [Cited by in Crossref: 20] [Cited by in F6Publishing: 6] [Article Influence: 6.7] [Reference Citation Analysis]
106 Waszczuk E, Waszczuk K, Bohdanowicz-Pawlak A, Florjański J. Women with inflammatory bowel diseases have a suboptimal cervical cancer screening rate and are not aware of the recommended human papilloma virus vaccine. Gynecol Endocrinol 2018;34:656-8. [PMID: 29475388 DOI: 10.1080/09513590.2017.1416466] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
107 Dembiński Ł, Stelmaszczyk-Emmel A, Sznurkowska K, Szlagatys-Sidorkiewicz A, Radzikowski A, Banaszkiewicz A. Immunogenicity of cholera vaccination in children with inflammatory bowel disease. Hum Vaccin Immunother 2021;17:2586-92. [PMID: 33794737 DOI: 10.1080/21645515.2021.1884475] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
108 Johnson J, Affolter K, Boynton K, Chen X, Valentine J, Peterson K. CMV Disease in IBD: Comparison of Diagnostic Tests and Correlation with Disease Outcome. Inflammatory Bowel Diseases 2018;24:1539-46. [DOI: 10.1093/ibd/izy045] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
109 Dipasquale V, Romano C. Pharmacological treatments and infectious diseases in pediatric inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2018;12:237-47. [PMID: 28994306 DOI: 10.1080/17474124.2018.1391091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
110 Wehkamp J, Götz M, Herrlinger K, Steurer W, Stange EF. Inflammatory Bowel Disease. Dtsch Arztebl Int 2016;113:72-82. [PMID: 26900160 DOI: 10.3238/arztebl.2016.0072] [Cited by in Crossref: 20] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
111 Hindryckx P, Novak G, Bonovas S, Peyrin-biroulet L, Danese S. Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel Disease. Clin Pharmacol Ther 2017;102:633-41. [DOI: 10.1002/cpt.791] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 5.8] [Reference Citation Analysis]
112 Rosiou K, Selinger CP. Acute severe ulcerative colitis: management advice for internal medicine and emergency physicians. Intern Emerg Med 2021;16:1433-42. [PMID: 33754227 DOI: 10.1007/s11739-021-02704-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
113 Loubet P, Verger P, Abitbol V, Peyrin-Biroulet L, Launay O. Pneumococcal and influenza vaccine uptake in adults with inflammatory bowel disease in France: Results from a web-based study. Dig Liver Dis 2018;50:563-7. [PMID: 29371056 DOI: 10.1016/j.dld.2017.12.027] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
114 Brooks AJ, Smith PJ, Lindsay JO. Monitoring adolescents and young people with inflammatory bowel disease during transition to adult healthcare. Frontline Gastroenterol 2018;9:37-44. [PMID: 29484159 DOI: 10.1136/flgastro-2016-100747] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
115 Lai HC, Chang CH, Cheng KS, Chen TW, Tsai YY, Chou JW. QuantiFERON-TB Gold Test Conversion Is Associated with Active Tuberculosis Development in Inflammatory Bowel Disease Patients Treated with Biological Agents: An Experience of a Medical Center in Taiwan. Gastroenterol Res Pract 2019;2019:7132875. [PMID: 31781198 DOI: 10.1155/2019/7132875] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
116 Lv YL, Han FF, Jia YJ, Wan ZR, Gong LL, Liu H, Liu LH. Is cytomegalovirus infection related to inflammatory bowel disease, especially steroid-resistant inflammatory bowel disease? Infect Drug Resist. 2017;10:511-519. [PMID: 29276397 DOI: 10.2147/idr.s149784] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 3.8] [Reference Citation Analysis]
117 van der Sloot KWJ, Voskuil MD, Blokzijl T, Dinkla A, Ravesloot L, Visschedijk MC, van Dullemen HM, Festen EAM, Alizadeh BZ, van Leer-Buter C, Weersma RK, van Goor H, Koets AP, Dijkstra G. Isotype-specific Antibody Responses to Mycobacterium avium paratuberculosis Antigens Are Associated With the Use of Biologic Therapy in Inflammatory Bowel Disease. J Crohns Colitis 2021;15:1253-63. [PMID: 33378524 DOI: 10.1093/ecco-jcc/jjaa263] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Ferretti F, Cannatelli R, Benucci M, Carmagnola S, Clementi E, Danelli P, Dilillo D, Fiorina P, Galli M, Gallieni M, Genovese G, Giorgi V, Invernizzi A, Maconi G, Maier JA, Marzano AV, Morpurgo PS, Nebuloni M, Radovanovic D, Riva A, Rizzardini G, Sabiu G, Santus P, Staurenghi G, Zuccotti G, Sarzi-Puttini PC, Ardizzone S. How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group. Front Immunol 2021;12:656362. [PMID: 33936084 DOI: 10.3389/fimmu.2021.656362] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
119 Koffas A, Dolman GE, Kennedy PT. Hepatitis B virus reactivation in patients treated with immunosuppressive drugs: a practical guide for clinicians. Clin Med (Lond). 2018;18:212-218. [PMID: 29858430 DOI: 10.7861/clinmedicine.18-3-212] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 7.5] [Reference Citation Analysis]
120 Taylor K, Gibson PR. Conventional Therapy of Ulcerative Colitis: Corticosteroids. In: Baumgart DC, editor. Crohn's Disease and Ulcerative Colitis. Cham: Springer International Publishing; 2017. pp. 399-412. [DOI: 10.1007/978-3-319-33703-6_39] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
121 Ko MK, Ng SC, Mak L, Li MK, Lo FH, Ng CKM, Lao WC, Tsang S, Chan KH, Hui YT, Shan EHS, Loo CK, Hui AJ, To WP, Hung IF, Leung WK. Infection-related hospitalizations in the first year after inflammatory bowel disease diagnosis: Infection in new IBD patients. Journal of Digestive Diseases 2016;17:610-7. [DOI: 10.1111/1751-2980.12397] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
122 Albarrak AA, Romana BS, Uraz S, Yousef MH, Juboori AA, Tahan V. Clostridium Difficile Infection in Inflammatory Bowel Disease Patients. Endocr Metab Immune Disord Drug Targets 2019;19:929-35. [PMID: 30827274 DOI: 10.2174/1871530319666190301120558] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
123 Pillet S, Pozzetto B, Roblin X. Cytomegalovirus and ulcerative colitis: Place of antiviral therapy. World J Gastroenterol. 2016;22:2030-2045. [PMID: 26877608 DOI: 10.3748/wjg.v22.i6.2030] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 33] [Article Influence: 9.8] [Reference Citation Analysis]
124 Nam K, Park SH, Lee J, Jo S, Kim SO, Noh S, Park JC, Kim JY, Kim J, Ham NS, Oh EH, Song EM, Hwang SW, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK. Incidence and risk factors of Pneumocystis jirovecii pneumonia in Korean patients with inflammatory bowel disease. J Gastroenterol Hepatol 2020;35:218-24. [PMID: 31412420 DOI: 10.1111/jgh.14832] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
125 Nakase H, Onodera K. Targeting cytomegalovirus during ulcerative colitis flare-ups. Expert Rev Gastroenterol Hepatol 2016;10:1119-25. [PMID: 27211020 DOI: 10.1080/17474124.2016.1192461] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
126 Wei SC, Chang TA, Chao TH, Chen JS, Chou JW, Chou YH, Chuang CH, Hsu WH, Huang TY, Hsu TC, Lin CC, Lin HH, Lin JK, Lin WC, Ni YH, Shieh MJ, Shih IL, Shun CT, Tsang YM, Wang CY, Wang HY, Weng MT, Wu DC, Wu WC, Yen HH, Wong JM. Management of Crohn's disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease. Intest Res 2017;15:285-310. [PMID: 28670226 DOI: 10.5217/ir.2017.15.3.285] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
127 Kosmidou M, Karavasili NT, Saridi M, Skamnelos A, Kavvadias A, Batistatou A, Gartzonika KG, Tsiara S, Katsanos KH, Christodoulou DK. Clostridium Difficile Infection in Patients Impact Suspected Cytomegalovirus Infection in Patients with Inflammatory Bowel Disease. Mater Sociomed 2020;32:41-5. [PMID: 32410890 DOI: 10.5455/msm.2020.32.41-45] [Reference Citation Analysis]
128 O'hara KM, Pontrelli G, Kunstel KL. An introduction to gastrointestinal tract CMV disease. Journal of the American Academy of Physician Assistants 2017;30:48-52. [DOI: 10.1097/01.jaa.0000524712.40590.76] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
129 Lawrence SJ, Sadarangani M, Jacobson K. Pneumocystis jirovecii Pneumonia in Pediatric Inflammatory Bowel Disease: A Case Report and Literature Review. Front Pediatr 2017;5:161. [PMID: 28791279 DOI: 10.3389/fped.2017.00161] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
130 Vuitton L, Jacquin E, Parmentier AL, Crochet E, Fein F, Dupont-Gossart AC, Plastaras L, Bretagne CH, Mauny F, Koch S, Prétet JL, Mougin C, Valmary-Degano S. High Prevalence of Anal Canal High-Risk Human Papillomavirus Infection in Patients With Crohn's Disease. Clin Gastroenterol Hepatol 2018;16:1768-1776.e5. [PMID: 29551740 DOI: 10.1016/j.cgh.2018.03.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
131 Caldera F, Saha S, Wald A, Garmoe CA, McCrone S, Megna B, Ley D, Reichelderfer M, Hayney MS. Lower Sustained Diphtheria and Pertussis Antibody Concentrations in Inflammatory Bowel Disease Patients. Dig Dis Sci 2018;63:1532-40. [PMID: 29594970 DOI: 10.1007/s10620-018-5043-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
132 Leszczyszyn JJ, Radomski M, Leszczyszyn AM. Intestinal microbiota transplant - current state of knowledge. Reumatologia 2016;54:24-8. [PMID: 27407273 DOI: 10.5114/reum.2016.58758] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
133 Deepak P, Park SH, Ehman EC, Hansel SL, Fidler JL, Bruining DH, Fletcher JG. Crohn’s disease diagnosis, treatment approach, and management paradigm: what the radiologist needs to know. Abdom Radiol 2017;42:1068-86. [DOI: 10.1007/s00261-017-1068-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
134 Pugliese D, Felice C, Papa A, Gasbarrini A, Rapaccini GL, Guidi L, Armuzzi A. Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future. Expert Rev Clin Immunol 2017;13:223-33. [PMID: 27687496 DOI: 10.1080/1744666X.2017.1243468] [Cited by in Crossref: 32] [Cited by in F6Publishing: 14] [Article Influence: 6.4] [Reference Citation Analysis]
135 van Rheenen PF. Managing abnormal liver tests in children with inflammatory bowel disease. Curr Opin Pediatr 2021;33:521-9. [PMID: 34261897 DOI: 10.1097/MOP.0000000000001045] [Reference Citation Analysis]
136 Chang K, Lee HS, Kim YJ, Kim SO, Kim SH, Lee SH, Song EM, Hwang SW, Park SH, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK. Increased Risk of Herpes Zoster Infection in Patients With Inflammatory Bowel Diseases in Korea. Clin Gastroenterol Hepatol 2018; 16: 1928-1936. e2. [PMID: 29857150 DOI: 10.1016/j.cgh.2018.05.024] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 9.7] [Reference Citation Analysis]
137 Losurdo G, Iannone A, Contaldo A, Barone M, Ierardi E, Di Leo A, Principi M. Chronic Viral Hepatitis in a Cohort of Inflammatory Bowel Disease Patients from Southern Italy: A Case-Control Study. Pathogens. 2020;9. [PMID: 33113974 DOI: 10.3390/pathogens9110870] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
138 Seah D, De Cruz P. Review article: the practical management of acute severe ulcerative colitis. Aliment Pharmacol Ther. 2016;43:482-513. [PMID: 26725569 DOI: 10.1111/apt.13491] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 10.0] [Reference Citation Analysis]
139 Berte' R, Mazza S, Stefanucci MR, Noviello D, Costa S, Ciafardini C, Mileti E, Mapelli M, Pasqualato S, Pinto S, Favale A, Vecchi M, Neurath MF, Atreya R, Fantini MC, Facciotti F, Caprioli F. Seroprevalence of SARS-CoV2 in IBD Patients Treated with Biologic Therapy. J Crohns Colitis 2021;15:864-8. [PMID: 33211810 DOI: 10.1093/ecco-jcc/jjaa237] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
140 Ciccocioppo R, Racca F, Scudeller L, Piralla A, Formagnana P, Pozzi L, Betti E, Vanoli A, Riboni R, Kruzliak P, Baldanti F, Corazza GR. Differential cellular localization of Epstein-Barr virus and human cytomegalovirus in the colonic mucosa of patients with active or quiescent inflammatory bowel disease. Immunol Res 2016;64:191-203. [PMID: 26659090 DOI: 10.1007/s12026-015-8737-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 3.4] [Reference Citation Analysis]
141 Alonso-sierra M, Calvo M, González-lama Y. Nocardia and Aspergillus Coinfection in a Patient with Ulcerative Colitis during Golimumab Therapy. ECCOJC 2016;10:1127-8. [DOI: 10.1093/ecco-jcc/jjw064] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
142 Abreu C, Sarmento A, Magro F. Reintroduction of Anti-TNFα Therapy After (or even During) Anti-TNFα-associated Tuberculosis in Immune-mediated Diseases: Table 1. ECCOJC 2015;10:120-1. [DOI: 10.1093/ecco-jcc/jjv172] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
143 de Francisco R, Castaño-García A, Martínez-González S, Pérez-Martínez I, González-Huerta AJ, Morais LR, Fernández-García MS, Jiménez S, Díaz-Coto S, Flórez-Díez P, Suárez A, Riestra S. Impact of Epstein-Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease. Aliment Pharmacol Ther 2018;48:723-30. [PMID: 30095176 DOI: 10.1111/apt.14933] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
144 Axiaris G, Zampeli E, Michopoulos S, Bamias G. Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment. World J Gastroenterol 2021;27:3762-79. [PMID: 34321842 DOI: 10.3748/wjg.v27.i25.3762] [Reference Citation Analysis]
145 Gong SS, Fan YH, Han QQ, Lv B, Xu Y. Nested case-control study on risk factors for opportunistic infections in patients with inflammatory bowel disease. World J Gastroenterol. 2019;25:2240-2250. [PMID: 31143074 DOI: 10.3748/wjg.v25.i18.2240] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
146 Cintolo M, Guarneri C, Lentini M. A Case of Molluscum Contagiosum Infection in a Patient with Crohn’s Disease, Receiving Combination Therapy with Azathioprine and Adalimumab: Figure 1. ECCOJC 2015;9:593-4. [DOI: 10.1093/ecco-jcc/jjv069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
147 Hashash JG, Jabak S, Francis FF, Regueiro M. Should We Be Screening for SARS-CoV-2 in IBD Patients Before Initiation of Biologic Therapy? Inflamm Bowel Dis. 2021;27:291-294. [PMID: 32619000 DOI: 10.1093/ibd/izaa173] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
148 Yamamoto-Furusho JK, Sarmiento-Aguilar A, Parra-Holguín NN, Bozada-Gutiérrez KE. Evaluation of a vaccination regimen and care in relation to follow-up and treatment of patients with inflammatory bowel disease. Rev Gastroenterol Mex (Engl Ed) 2019;84:11-7. [PMID: 29605092 DOI: 10.1016/j.rgmx.2018.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
149 Guillo L, Rabaud C, Choy EH, D'Amico F, Danese S, Ng SC, Peyrin-Biroulet L. Herpes Zoster and Vaccination Strategies in Inflammatory Bowel Diseases: A Practical Guide. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31440-3. [PMID: 33080353 DOI: 10.1016/j.cgh.2020.10.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
150 Wethkamp N, Nordlohne EM, Meister V, Helwig U, Respondek M. Identification of clinically relevant cytomegalovirus infections in patients with inflammatory bowel disease. Mod Pathol 2018;31:527-38. [PMID: 29192648 DOI: 10.1038/modpathol.2017.149] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
151 Fidan S, Capkın E, Arıca DA, Durak S, Okatan IE. Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-α therapy. Int J Rheum Dis 2021;24:254-9. [PMID: 33244900 DOI: 10.1111/1756-185X.14034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
152 Feng S, Lin S, Ma L, Xu S, Chen Y. Insufficient Knowledge and Vaccination Practice of Inflammatory Bowel Disease Patients in the People's Republic of China. Patient Prefer Adherence. 2020;14:1513-1521. [PMID: 32943848 DOI: 10.2147/ppa.s265346] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
153 Ellul P, Zammita SC, Katsanos KH, Cesarini M, Allocca M, Danese S, Karatzas P, Moreno SC, Kopylov U, Fiorino G. Perception of Reproductive Health in Women with Inflammatory Bowel Disease. J Crohns Colitis. 2016;10:886-891. [PMID: 26783343 DOI: 10.1093/ecco-jcc/jjw011] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
154 Dellière S, Gits-Muselli M, Bretagne S, Alanio A. Outbreak-Causing Fungi: Pneumocystis jirovecii. Mycopathologia 2020;185:783-800. [PMID: 31782069 DOI: 10.1007/s11046-019-00408-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
155 Fiorino G, Bonovas S, Cicerone C, Allocca M, Furfaro F, Correale C, Danese S. The safety of biological pharmacotherapy for the treatment of ulcerative colitis. Expert Opin Drug Saf. 2017;16:437-443. [PMID: 28279079 DOI: 10.1080/14740338.2017.1298743] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
156 Tun GSZ, Raza M, Hale MF, Lobo AJ. Polymerase chain reaction for detection of mucosal cytomegalovirus infection in patients with acute ulcerative colitis. Ann Gastroenterol 2019;32:81-7. [PMID: 30598596 DOI: 10.20524/aog.2018.0318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
157 Lopez A, Mariette X, Bachelez H, Belot A, Bonnotte B, Hachulla E, Lahfa M, Lortholary O, Loulergue P, Paul S. Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis. J Autoimmun. 2017;80:10-27. [PMID: 28381345 DOI: 10.1016/j.jaut.2017.03.011] [Cited by in Crossref: 69] [Cited by in F6Publishing: 50] [Article Influence: 17.3] [Reference Citation Analysis]
158 Gabbani T, Deiana S, Lunardi S, Manetti N, Annese V. Safety profile of methotrexate in inflammatory bowel disease. Expert Opinion on Drug Safety 2016;15:1427-37. [DOI: 10.1080/14740338.2016.1218468] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
159 Chang JY, Cheon JH. Thiopurine Therapy in Patients With Inflammatory Bowel Disease: A Focus on Metabolism and Pharmacogenetics. Dig Dis Sci 2019;64:2395-403. [PMID: 31290039 DOI: 10.1007/s10620-019-05720-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
160 Loras C, Gisbert J, Saro M, Piqueras M, Sánchez-montes C, Barrio J, Ordás I, Montserrat A, Ferreiro R, Zabana Y, Chaparro M, Fernández-bañares F, Esteve M. Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: Multicenter prospective observational study (REPENTINA 3). Journal of Crohn's and Colitis 2014;8:1529-38. [DOI: 10.1016/j.crohns.2014.06.009] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
161 Cekic C, Aslan F, Kirci A, Gümüs ZZ, Arabul M, Yüksel ES, Vatansever S, Yurtsever SG, Alper E, Ünsal B. Evaluation of factors associated with response to hepatitis B vaccination in patients with inflammatory bowel disease. Medicine (Baltimore) 2015;94:e940. [PMID: 26039133 DOI: 10.1097/MD.0000000000000940] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
162 Khan N, Trivedi C, Kavani H, Medvedeva E, Lewis J, Yang Y. Efficacy of Live Attenuated Herpes Zoster Vaccine in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology 2019;17:1341-7. [DOI: 10.1016/j.cgh.2018.10.016] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 8.5] [Reference Citation Analysis]
163 Jones JL, Tse F, Carroll MW, deBruyn JC, McNeil SA, Pham-Huy A, Seow CH, Barrett LL, Bessissow T, Carman N, Melmed GY, Vanderkooi OG, Marshall JK, Benchimol EI. Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)-Part 2: Inactivated Vaccines. Gastroenterology 2021;161:681-700. [PMID: 34334167 DOI: 10.1053/j.gastro.2021.04.034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
164 Kumric M, Ticinovic Kurir T, Martinovic D, Zivkovic PM, Bozic J. Impact of the COVID-19 pandemic on inflammatory bowel disease patients: A review of the current evidence. World J Gastroenterol 2021;27:3748-61. [PMID: 34321841 DOI: 10.3748/wjg.v27.i25.3748] [Reference Citation Analysis]
165 Mak JW, Sung JJ. The Use of Biologics and Biosimilar in Asian patients with IBD: Are we ready? J Gastroenterol Hepatol 2019;34:1269-70. [PMID: 31456235 DOI: 10.1111/jgh.14817] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
166 Kucharzik T, Ellul P, Greuter T, Rahier JF, Verstockt B, Abreu C, Albuquerque A, Allocca M, Esteve M, Farraye FA, Gordon H, Karmiris K, Kopylov U, Kirchgesner J, MacMahon E, Magro F, Maaser C, de Ridder L, Taxonera C, Toruner M, Tremblay L, Scharl M, Viget N, Zabana Y, Vavricka S. ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. J Crohns Colitis 2021;15:879-913. [PMID: 33730753 DOI: 10.1093/ecco-jcc/jjab052] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
167 Komoto S, Matsuoka K, Kobayashi T, Yokoyama Y, Suzuki Y, Hibi T, Miura S, Hokari R. Safety and efficacy of leukocytapheresis in elderly patients with ulcerative colitis: The impact in steroid-free elderly patients. J Gastroenterol Hepatol 2018;33:1485-91. [PMID: 29406567 DOI: 10.1111/jgh.14116] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
168 Dembiński Ł, Dziekiewicz M, Banaszkiewicz A. Immune Response to Vaccination in Children and Young People With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Journal of Pediatric Gastroenterology & Nutrition 2020;71:423-32. [DOI: 10.1097/mpg.0000000000002810] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
169 Jafri H, Kalina DR, Aziz T, Serrano PE, Haider S. Herpes Simplex Virus Colitis in a Patient with Newly Diagnosed Crohn's Disease. Case Rep Med. 2018;2018:7591709. [PMID: 30013599 DOI: 10.1155/2018/7591709] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
170 Macaluso FS, Cottone M, Orlando A. Risk of Pneumonia Caused by Pneumocystis jiroveci in Inflammatory Bowel Disease: The Role of Concomitant Pulmonary Comorbidities. Clinical Gastroenterology and Hepatology 2019;17:571-2. [DOI: 10.1016/j.cgh.2017.06.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
171 Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H;  IBD guidelines eDelphi consensus group; Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1-s106. [PMID: 31562236 DOI: 10.1136/gutjnl-2019-318484] [Cited by in Crossref: 361] [Cited by in F6Publishing: 256] [Article Influence: 180.5] [Reference Citation Analysis]
172 Carpio D, Jauregui-amezaga A, de Francisco R, de Castro L, Barreiro-de Acosta M, Mendoza JL, Mañosa M, Ollero V, Castro B, González-conde B, Hervías D, Sierra Ausin M, Sancho del Val L, Botella-mateu B, Martínez-cadilla J, Calvo M, Chaparro M, Ginard D, Guerra I, Maroto N, Calvet X, Fernández-salgado E, Gordillo J, Rojas Feria M. Tuberculosis in Anti-Tumour Necrosis Factor-treated Inflammatory Bowel Disease Patients After the Implementation of Preventive Measures: Compliance With Recommendations and Safety of Retreatment. ECCOJC 2016;10:1186-93. [DOI: 10.1093/ecco-jcc/jjw022] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 5.2] [Reference Citation Analysis]
173 Pillet S, Jarlot C, Courault M, Del Tedesco E, Chardon R, Saint-Sardos P, Presles E, Phelip JM, Berthelot P, Pozzetto B, Roblin X. Infliximab Does Not Worsen Outcomes During Flare-ups Associated with Cytomegalovirus Infection in Patients with Ulcerative Colitis. Inflamm Bowel Dis. 2015;21:1580-1586. [PMID: 25933392 DOI: 10.1097/mib.0000000000000412] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
174 Ye L, Chapman TP, Wen Z, Lin L, Qiu Y, Liu Z, Ran Z, Qian J, Wu K, Gao X, Hu P, Chen M, Travis SPL, Cao Q; Chinese IBD Elite Union. Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti-TNF therapy in a tuberculosis endemic region. Aliment Pharmacol Ther 2021;53:390-9. [PMID: 33314259 DOI: 10.1111/apt.16130] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
175 Shivaji UN, Sharratt CL, Thomas T, Smith SCL, Iacucci M, Moran GW, Ghosh S, Bhala N. Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2019;49:664-80. [DOI: 10.1111/apt.15097] [Cited by in Crossref: 41] [Cited by in F6Publishing: 28] [Article Influence: 20.5] [Reference Citation Analysis]
176 Zabana Y, Rodríguez L, Lobatón T, Gordillo J, Montserrat A, Mena R, Beltrán B, Dotti M, Benitez O, Guardiola J, Domènech E, Garcia-Planella E, Calvet X, Piqueras M, Aceituno M, Fernández-Bañares F, Esteve M. Relevant Infections in Inflammatory Bowel Disease, and Their Relationship With Immunosuppressive Therapy and Their Effects on Disease Mortality. J Crohns Colitis 2019;13:828-37. [PMID: 30668662 DOI: 10.1093/ecco-jcc/jjz013] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 28.0] [Reference Citation Analysis]
177 Paramsothy S. Travel risk management. J Gastroenterol Hepatol 2021;36 Suppl 1:32-3. [PMID: 33817845 DOI: 10.1111/jgh.15460] [Reference Citation Analysis]
178 Whaley KG, Rosen MJ. Contemporary Medical Management of Acute Severe Ulcerative Colitis. Inflamm Bowel Dis 2019;25:56-66. [PMID: 29889235 DOI: 10.1093/ibd/izy208] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
179 Zhu M, Ran Z. Clinical characteristics of ulcerative colitis in elderly patients. JGH Open 2021;5:849-54. [PMID: 34386591 DOI: 10.1002/jgh3.12612] [Reference Citation Analysis]
180 Christensen KR, Steenholdt C, Buhl SS, Ainsworth MA, Thomsen OØ, Brynskov J. Systematic Information to Health-Care Professionals about Vaccination Guidelines Improves Adherence in Patients With Inflammatory Bowel Disease in Anti-TNFα Therapy. Am J Gastroenterol 2015;110:1526-32. [PMID: 26032156 DOI: 10.1038/ajg.2015.162] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
181 Hong SN, Kim HJ, Kim KH, Han SJ, Ahn IM, Ahn HS. Risk of incident Mycobacterium tuberculosis infection in patients with inflammatory bowel disease: a nationwide population-based study in South Korea. Aliment Pharmacol Ther. 2017;45:253-263. [PMID: 27933686 DOI: 10.1111/apt.13851] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
182 Orlandini B, Dragoni G, Variola A, Massella A, Bagnoli S, Campi R, Rogai F. Clinical efficacy and safety of golimumab in biologically experienced and naive patients with active ulcerative colitis: A real-life experience from two Italian IBD centers. J Dig Dis 2018;19:468-74. [PMID: 30039533 DOI: 10.1111/1751-2980.12648] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
183 Strasse KLA, Jamur CM, Marques J, Kim MSM, Petterle RR, Amarante HMBDS. IMMUNIZATION STATUS OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE. Arq Gastroenterol 2019;56:124-30. [PMID: 31460574 DOI: 10.1590/S0004-2803.201900000-26] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
184 Antonelli E, Bassotti G, Tramontana M, Hansel K, Stingeni L, Ardizzone S, Genovese G, Marzano AV, Maconi G. Dermatological Manifestations in Inflammatory Bowel Diseases. J Clin Med 2021;10:364. [PMID: 33477990 DOI: 10.3390/jcm10020364] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
185 Wellens J, Colombel JF, Satsangi JJ, Wong SY. SARS-CoV-2 Vaccination in IBD: Past Lessons, Current Evidence, and Future Challenges. J Crohns Colitis 2021;15:1376-86. [PMID: 33721882 DOI: 10.1093/ecco-jcc/jjab046] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
186 Rouiller-Braunschweig C, Fournier N, Pittet V, Dudler J, Michetti P. Efficacy, Safety and Mucosal Healing of Methotrexate in a Large Longitudinal Cohort of Inflammatory Bowel Disease Patients. Digestion 2017;96:220-7. [PMID: 29065423 DOI: 10.1159/000482007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
187 Kowalska-Duplaga K, Baranowska-Nowak M, Nescioruk M, Banasiuk M, Karolewska-Bochenek K, Łazowska-Przeorek I, Radzikowski A, Banaszkiewicz A. Immunization Coverage in Children with Inflammatory Bowel Disease. Adv Exp Med Biol 2019;1113:83-8. [PMID: 29429027 DOI: 10.1007/5584_2018_163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
188 Park SC, Jeen YM, Jeen YT. Approach to cytomegalovirus infections in patients with ulcerative colitis. Korean J Intern Med 2017;32:383-92. [PMID: 28490715 DOI: 10.3904/kjim.2017.087] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
189 Schleker T, Jacobsen EM, Mayer B, Strauss G, Debatin KM, Posovszky C. Preserved in vitro immunoreactivity in children receiving long-term immunosuppressive therapy due to inflammatory bowel disease or autoimmune hepatitis. Mol Cell Pediatr 2018;5:1. [PMID: 29352427 DOI: 10.1186/s40348-018-0079-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
190 Samaan M, Campbell S, Cunningham G, Tamilarasan AG, Irving PM, McCartney S. Biologic therapies for Crohn's disease: optimising the old and maximising the new. F1000Res 2019;8:F1000 Faculty Rev-1210. [PMID: 31448080 DOI: 10.12688/f1000research.18902.1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
191 Mantzaris GJ. Thiopurines and Methotrexate Use in IBD Patients in a Biologic Era. Curr Treat Options Gastro 2017;15:84-104. [DOI: 10.1007/s11938-017-0128-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
192 Oliva S, Thomson M, de Ridder L, Martín-de-Carpi J, Van Biervliet S, Braegger C, Dias JA, Kolacek S, Miele E, Buderus S, Bronsky J, Winter H, Navas-López VM, Assa A, Chong SKF, Afzal NA, Smets F, Shaoul R, Hussey S, Turner D, Cucchiara S. Endoscopy in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto IBD Group of the European Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:414-30. [PMID: 30130311 DOI: 10.1097/MPG.0000000000002092] [Cited by in Crossref: 31] [Cited by in F6Publishing: 8] [Article Influence: 15.5] [Reference Citation Analysis]
193 Oh EH, Kim J, Ham N, Hwang SW, Park SH, Yang DH, Byeon JS, Myung SJ, Yang SK, Ye BD. Long-term Outcomes of Adalimumab Therapy in Korean Patients with Ulcerative Colitis: A Hospital-Based Cohort Study. Gut Liver 2020;14:347-56. [PMID: 31530738 DOI: 10.5009/gnl19137] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
194 Zapater P, Almenara S, Gutiérrez A, Sempere L, García M, Laveda R, Martínez A, Scharl M, Cameo JI, Linares R, González-Navajas JM, Wiest R, Rogler G, Francés R. Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn's Disease. Inflamm Bowel Dis 2019;25:1357-66. [PMID: 30776076 DOI: 10.1093/ibd/izz012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
195 Jain S, Ahuja V, Limdi JK. Optimal management of acute severe ulcerative colitis. Postgrad Med J. 2019;95:32-40. [PMID: 30636193 DOI: 10.1136/postgradmedj-2018-136072] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
196 Hradsky O, Copova I, Zarubova K, Durilova M, Nevoral J, Maminak M, Hubacek P, Bronsky J. Seroprevalence of Epstein–Barr Virus, Cytomegalovirus, and Polyomaviruses in Children with Inflammatory Bowel Disease. Dig Dis Sci 2015;60:3399-407. [DOI: 10.1007/s10620-015-3764-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
197 Tursi A, Mocci G, Lorenzetti R, Allegretta L, Brandimarte G, Cassieri C, Colucci R, De Medici A, Faggiani R, Ferronato A, Fiorella S, Forti G, Franceschi M, Gallina S, Giorgetti G, Grasso G, Larussa T, Luzza F, Penna A, Pica R, Piergallini S, Porciello S, Pranzo G, Rodino' S, Scorza S, Sebkova L, Zampaletta C, Elisei W, Picchio M. Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients. Eur J Gastroenterol Hepatol 2021;33:670-9. [PMID: 33741797 DOI: 10.1097/MEG.0000000000002087] [Reference Citation Analysis]
198 Wei SC, Chang TA, Chao TH, Chen JS, Chou JW, Chou YH, Chuang CH, Hsu WH, Huang TY, Hsu TC, Lin CC, Lin HH, Lin JK, Lin WC, Ni YH, Shieh MJ, Shih IL, Shun CT, Tsang YM, Wang CY, Wang HY, Weng MT, Wu DC, Wu WC, Yen HH, Wong JM. Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease.Intest Res. 2017;15:266-284. [PMID: 28670225 DOI: 10.5217/ir.2017.15.3.266] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
199 Sarzi-Puttini P, Giorgi V, Sirotti S, Marotto D, Ardizzone S, Rizzardini G, Antinori S, Galli M. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Clin Exp Rheumatol. 2020;38:337-342. [PMID: 32202240 DOI: 10.1016/j.autrev.2020.102574] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 24.0] [Reference Citation Analysis]
200 Gauss A, Rosenstiel S, Schnitzler P, Hinz U, Rehlen T, Kadmon M, Ehehalt R, Stremmel W, Zawierucha A. Intestinal cytomegalovirus infection in patients hospitalized for exacerbation of inflammatory bowel disease: a 10-year tertiary referral center experience. Eur J Gastroenterol Hepatol. 2015;27:712-720. [PMID: 25919654 DOI: 10.1097/meg.0000000000000361] [Cited by in Crossref: 26] [Cited by in F6Publishing: 9] [Article Influence: 5.2] [Reference Citation Analysis]
201 Haag LM, Hofmann J, Kredel LI, Holzem C, Kühl AA, Taube ET, Schubert S, Siegmund B, Epple HJ. Herpes Simplex Virus Sepsis in a Young Woman with Crohn's Disease. J Crohns Colitis 2015;9:1169-73. [PMID: 26351382 DOI: 10.1093/ecco-jcc/jjv149] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
202 Ben-Horin S, Van Assche G, Chowers Y, Fudim E, Ungar B, Picard O, Yavzori M, Kopylov U, Mao R, Chen MH, Peled Y, Gueta I, Eliakim R, Loebstein R, Markovits N. Pharmacokinetics and Immune Reconstitution Following Discontinuation of Thiopurine Analogues: Implications for Drug Withdrawal Strategies. J Crohns Colitis 2018;12:1410-7. [PMID: 30169593 DOI: 10.1093/ecco-jcc/jjy122] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
203 Rodríguez de Santiago E, Albillos Martínez A, López-Sanromán A. Infections in inflammatory bowel disease. Med Clin (Barc) 2017;148:415-23. [PMID: 28233560 DOI: 10.1016/j.medcli.2016.12.041] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
204 Ungaro RC, Brenner EJ, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, Ng SC, Rahier JF, Reinisch W, Steinwurz F, Underwood FE, Zhang X, Colombel JF, Kappelman MD. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut 2021;70:725-32. [PMID: 33082265 DOI: 10.1136/gutjnl-2020-322539] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 59.0] [Reference Citation Analysis]
205 Xu S, Chen H, Zu X, Hao X, Feng R, Zhang S, Chen B, Zeng Z, Chen M, Ye Z, He Y. Epstein-Barr virus infection in ulcerative colitis: a clinicopathologic study from a Chinese area. Therap Adv Gastroenterol 2020;13:1756284820930124. [PMID: 32913442 DOI: 10.1177/1756284820930124] [Reference Citation Analysis]
206 Dulai PS, Buckey JC Jr, Raffals LE, Swoger JM, Claus PL, OʼToole K, Ptak JA, Gleeson MW, Widjaja CE, Chang JT, Adler JM, Patel N, Skinner LA, Haren SP, Goldby-Reffner K, Thompson KD, Siegel CA. Hyperbaric oxygen therapy is well tolerated and effective for ulcerative colitis patients hospitalized for moderate-severe flares: a phase 2A pilot multi-center, randomized, double-blind, sham-controlled trial. Am J Gastroenterol 2018;113:1516-23. [PMID: 29453383 DOI: 10.1038/s41395-018-0005-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
207 Tektonidou MG, Wang Z, Dasgupta A, Ward MM. Burden of Serious Infections in Adults With Systemic Lupus Erythematosus: A National Population-Based Study, 1996-2011. Arthritis Care Res (Hoboken) 2015;67:1078-85. [PMID: 25732901 DOI: 10.1002/acr.22575] [Cited by in Crossref: 76] [Cited by in F6Publishing: 54] [Article Influence: 12.7] [Reference Citation Analysis]
208 Gecse KB, Vermeire S. Differential diagnosis of inflammatory bowel disease: imitations and complications. Lancet Gastroenterol Hepatol 2018;3:644-53. [PMID: 30102183 DOI: 10.1016/S2468-1253(18)30159-6] [Cited by in Crossref: 34] [Cited by in F6Publishing: 13] [Article Influence: 11.3] [Reference Citation Analysis]
209 Yang H, Zhou W, Lv H, Wu D, Feng Y, Shu H, Jin M, Hu L, Wang Q, Wu D, Chen J, Qian J. The Association Between CMV Viremia or Endoscopic Features and Histopathological Characteristics of CMV Colitis in Patients with Underlying Ulcerative Colitis: . Inflammatory Bowel Diseases 2017;23:814-21. [DOI: 10.1097/mib.0000000000001095] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
210 Mourad FH, Hashash JG, Kariyawasam VC, Leong RW. Ulcerative Colitis and Cytomegalovirus Infection: From A to Z. J Crohns Colitis. 2020;14:1162-1171. [PMID: 32103246 DOI: 10.1093/ecco-jcc/jjaa036] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
211 Weng MT, Tung CC, Lee YS, Leong YL, Shieh MJ, Shun CT, Wang CY, Wong JM, Wei SC. Cytomegalovirus colitis in hospitalized inflammatory bowel disease patients in Taiwan: a referral center study. BMC Gastroenterol. 2017;17:28. [PMID: 28193173 DOI: 10.1186/s12876-017-0586-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
212 Kobayashi R, Matsumoto S, Yoshida Y. Tacrolimus Therapy for Three Patients with Elderly-Onset Ulcerative Colitis: Report of Three Cases. Case Rep Gastroenterol 2016;10:392-8. [PMID: 27721723 DOI: 10.1159/000447288] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
213 Bernstein CN, Eliakim A, Fedail S, Fried M, Gearry R, Goh KL, Hamid S, Khan AG, Khalif I, Ng SC, Ouyang Q, Rey JF, Sood A, Steinwurz F, Watermeyer G, LeMair A; Review Team:. World Gastroenterology Organisation Global Guidelines Inflammatory Bowel Disease: Update August 2015. J Clin Gastroenterol. 2016;50:803-818. [PMID: 27741097 DOI: 10.1097/mcg.0000000000000660] [Cited by in Crossref: 52] [Cited by in F6Publishing: 18] [Article Influence: 17.3] [Reference Citation Analysis]
214 Côté-Daigneault J, Bessissow T, Nicolae MV, Nie R, Bitton A, Lakatos PL, Brassard P. Herpes Zoster Incidence in Inflammatory Bowel Disease Patients: A Population-Based Study. Inflamm Bowel Dis 2019;25:914-8. [PMID: 30295818 DOI: 10.1093/ibd/izy311] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
215 Park DI, Hisamatsu T, Chen M, Ng SC, Ooi CJ, Wei SC, Banerjee R, Hilmi IN, Jeen YT, Han DS, Kim HJ, Ran Z, Wu K, Qian J, Hu P, Matsuoka K, Andoh A, Suzuki Y, Sugano K, Watanabe M, Hibi T, Puri AS, Yang S. Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: Risk assessment: AOCC & APAGE consensus on TB in IBD-Part 1. Journal of Gastroenterology and Hepatology 2018;33:20-9. [DOI: 10.1111/jgh.14019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
216 Schenk W, Klugmann T, Borkenhagen A, Klecker C, Dietel P, Kirschner R, Schneider E, Bruns T, Stallmach A, Teich N. The detection of the cytomegalovirus DNA in the colonic mucosa of patients with ulcerative colitis is associated with increased long-term risk of proctocolectomy: results from an outpatient IBD clinic. Int J Colorectal Dis. 2019;34:393-400. [PMID: 30506156 DOI: 10.1007/s00384-018-3210-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
217 Gomollón F, Rubio S, Charro M, García-López S, Muñoz F, Gisbert JP, Domènech E; En Representación de GETECCU. [Reccomendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of methotrexate in inflammatory bowel disease]. Gastroenterol Hepatol 2015;38:24-30. [PMID: 25454602 DOI: 10.1016/j.gastrohep.2014.10.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
218 Abdullah A, Neurath MF, Atreya R. Mild COVID-19 Symptoms in an Infliximab-Treated Ulcerative Colitis Patient: Can Ongoing Anti-TNF Therapy Protect against the Viral Hyperinflammatory Response and Avoid Aggravated Outcomes? Visc Med 2020;36:338-42. [PMID: 32999889 DOI: 10.1159/000508740] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
219 Oh SJ, Lee CK, Kim Y, Jeong SJ, Park YM, Oh CH, Kim J, Kim HJ. True cytomegalovirus colitis is a poor prognostic indicator in patients with ulcerative colitis flares: the 10-year experience of an academic referral inflammatory bowel disease center. Scandinavian Journal of Gastroenterology 2019;54:976-83. [DOI: 10.1080/00365521.2019.1646798] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
220 Lopetuso LR, Mocci G, Marzo M, D'Aversa F, Rapaccini GL, Guidi L, Armuzzi A, Gasbarrini A, Papa A. Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver. Int J Mol Sci 2018;19:E2199. [PMID: 30060508 DOI: 10.3390/ijms19082199] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
221 Ekenberg C, Friis-Møller N, Ulstrup T, Aalykke C. Inadvertent yellow fever vaccination of a patient with Crohn's disease treated with infliximab and methotrexate. BMJ Case Rep 2016;2016:bcr2016215403. [PMID: 27571912 DOI: 10.1136/bcr-2016-215403] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
222 Kelso M, Weideman RA, Cipher DJ, Feagins LA. Factors Associated With Length of Stay in Veterans With Inflammatory Bowel Disease Hospitalized for an Acute Flare. Inflamm Bowel Dis 2017;24:5-11. [PMID: 29272483 DOI: 10.1093/ibd/izx020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
223 Oliveira SB, Monteiro IM. Diagnosis and management of inflammatory bowel disease in children. BMJ. 2017;357:j2083. [PMID: 28566467 DOI: 10.1136/bmj.j2083] [Cited by in Crossref: 39] [Cited by in F6Publishing: 28] [Article Influence: 9.8] [Reference Citation Analysis]
224 Fleurier A, Pelatan C, Willot S, Ginies J, Breton E, Bridoux L, Segura J, Chaillou E, Jobert A, Darviot E, Cagnard B, Delaperriere N, Grimal I, Carre E, Wagner A, Sylvestre E, Dabadie A. Vaccination coverage of children with inflammatory bowel disease after an awareness campaign on the risk of infection. Digestive and Liver Disease 2015;47:460-4. [DOI: 10.1016/j.dld.2015.02.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
225 Ardura MI, Toussi SS, Siegel JD, Lu Y, Bousvaros A, Crandall W. NASPGHAN Clinical Report: Surveillance, Diagnosis, and Prevention of Infectious Diseases in Pediatric Patients With Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-α Inhibitors. Journal of Pediatric Gastroenterology & Nutrition 2016;63:130-55. [DOI: 10.1097/mpg.0000000000001188] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
226 Römkens TE, Bulte GJ, Nissen LH, Drenth JP. Cytomegalovirus in inflammatory bowel disease: A systematic review. World J Gastroenterol 2016;22:1321-30. [PMID: 26811669 DOI: 10.3748/wjg.v22.i3.1321] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 29] [Article Influence: 9.8] [Reference Citation Analysis]
227 Chan HC, Wong VW, Wong GL, Tang W, Wu JC, Ng SC. Prevalence of hepatitis B and clinical outcomes in inflammatory bowel disease patients in a viral-endemic region. BMC Gastroenterol. 2016;16:100. [PMID: 27549153 DOI: 10.1186/s12876-016-0516-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
228 Hissong E, Chen Z, Yantiss RK. Cytomegalovirus reactivation in inflammatory bowel disease: an uncommon occurrence related to corticosteroid dependence. Mod Pathol 2019;32:1210-6. [DOI: 10.1038/s41379-019-0258-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
229 Franklin C, Rooms I, Fiedler M, Reis H, Milsch L, Herz S, Livingstone E, Zimmer L, Schmid KW, Dittmer U, Schadendorf D, Schilling B. Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis. European Journal of Cancer 2017;86:248-56. [DOI: 10.1016/j.ejca.2017.09.019] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 7.8] [Reference Citation Analysis]
230 Joshi NM, Marks IH, Crowson R, Ball D, Rampton DS. Incidence and Outcome of Clostridium difficile Infection in Hospitalized Patients with Inflammatory Bowel Disease in the UK. ECCOJC 2016;11:70-6. [DOI: 10.1093/ecco-jcc/jjw117] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
231 Riestra S, Taxonera C, Carpio D, López-san Román A, Gisbert J, Domènech E. Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el cribado y tratamiento de la tuberculosis latente en pacientes con enfermedad inflamatoria intestinal. Enfermedad Inflamatoria Intestinal al Día 2015;14:109-19. [DOI: 10.1016/j.eii.2015.09.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
232 Edison N, Belhanes-Peled H, Eitan Y, Guthmann Y, Yeremenko Y, Raffeld M, Elmalah I, Trougouboff P. Indolent T-cell lymphoproliferative disease of the gastrointestinal tract after treatment with adalimumab in resistant Crohn's colitis. Hum Pathol 2016;57:45-50. [PMID: 27402301 DOI: 10.1016/j.humpath.2016.06.021] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
233 van der Woude CJ, Ardizzone S, Bengtson MB, Fiorino G, Fraser G, Katsanos K, Kolacek S, Juillerat P, Mulders AG, Pedersen N. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis. 2015;9:107-124. [PMID: 25602023 DOI: 10.1093/ecco-jcc/jju006] [Cited by in Crossref: 220] [Cited by in F6Publishing: 186] [Article Influence: 44.0] [Reference Citation Analysis]
234 Mazzola G, Macaluso FS, Adamoli L, Renna S, Cascio A, Orlando A. Diagnostic and vaccine strategies to prevent infections in patients with inflammatory bowel disease. J Infect. 2017;74:433-441. [PMID: 28263759 DOI: 10.1016/j.jinf.2017.02.009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
235 Khan N, Trivedi C, Kavani H, Lewis J, Yang YX. Frequency of Herpes Zoster Vaccination Among Inflammatory Bowel Disease Patients. Inflamm Bowel Dis 2019;25:345-51. [PMID: 29982646 DOI: 10.1093/ibd/izy232] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
236 Li SY, Li PW, Shen B, Zhi M, Gu YB, Wang XY, Guo H, Li Y, Fan YH, Yang BL, Xue M, Wang XY, Lv MF, Li Y, Ye B, Zhu XJ, Chen Y. Insufficient awareness and vaccination practices for inflammatory bowel disease patients in China: A multi-center survey of Chinese gastroenterologists. J Dig Dis 2020;21:46-51. [PMID: 31794121 DOI: 10.1111/1751-2980.12834] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
237 Campos ST, Portela FA, Tomé L. Cytomegalovirus, inflammatory bowel disease, and anti-TNFα. Int J Colorectal Dis 2017;32:645-50. [DOI: 10.1007/s00384-017-2752-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
238 Patil AP, Simon EG, Dutta AK, Joseph AJ, Kurien RT, Chowdhury SD. Prevalence of serological markers of hepatitis B in inflammatory bowel disease - Experience from a tertiary care centre in South India. Trop Doct 2021;51:326-31. [PMID: 34018886 DOI: 10.1177/00494755211015571] [Reference Citation Analysis]
239 Schreiner P, Mueller NJ, Fehr J, Maillard MH, Brand S, Michetti P, Schoepfer A, Restellini S, Vulliemoz M, Vavricka SR, Juillerat P, Rogler G, Biedermann L. Varicella zoster virus in inflammatory bowel disease patients: what every gastroenterologist should know. J Crohns Colitis. 2020;Online ahead of print. [PMID: 32592587 DOI: 10.1093/ecco-jcc/jjaa132] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
240 Assa A, Avni I, Ben-bassat O, Niv Y, Shamir R. Practice Variations in the Management of Inflammatory Bowel Disease Between Pediatric and Adult Gastroenterologists. Journal of Pediatric Gastroenterology & Nutrition 2016;62:372-7. [DOI: 10.1097/mpg.0000000000000943] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
241 Park SK, Choi CH, Chun J, Lee H, Kim ES, Park JJ, Park CH, Lee BI, Jung Y, Park DI, Kim DY, Park H, Jeen YT;  IBD Research Group of the Korean Association for the Study of Intestinal Diseases. Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases. Intest Res. 2020;18:18-33. [PMID: 32013312 DOI: 10.5217/ir.2019.09155] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
242 Yaccob A, Mari A. Practical clinical approach to the evaluation of hepatobiliary disorders in inflammatory bowel disease. Frontline Gastroenterol 2019;10:309-15. [PMID: 31281626 DOI: 10.1136/flgastro-2018-101037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
243 Wu XW, Yang MF, Li N, Wang FY. Unfavorable outcome of antiviral therapy in cytomegalovirus-positive ulcerative colitis may be due to inappropriate study inclusion in meta-analysis. World J Gastroenterol 2015;21:1689-90. [PMID: 25663793 DOI: 10.3748/wjg.v21.i5.1689] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
244 Ng SC, Hilmi IN, Blake A, Bhayat F, Adsul S, Khan QR, Wu DC. Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting.Inflamm Bowel Dis. 2018;24:2431-2441. [PMID: 30312414 DOI: 10.1093/ibd/izy153] [Cited by in Crossref: 43] [Cited by in F6Publishing: 27] [Article Influence: 21.5] [Reference Citation Analysis]
245 Harris RE, Hegde V, Curtis L, Garrick V, Gervais L, Armstrong L, Delahunty C, Eccleston A, Al-Hourani G, Flynn DM, Merrick V, Barclay AR, Tayler R, Hansen R, Russell RK. Epstein-Barr Virus Status and Subsequent Thiopurine Exposure Within a Paediatric Inflammatory Bowel Disease Population. J Pediatr Gastroenterol Nutr 2021;73:358-62. [PMID: 34091548 DOI: 10.1097/MPG.0000000000003197] [Reference Citation Analysis]
246 Colombel JF. Herpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention. Inflamm Bowel Dis 2018;24:2173-82. [PMID: 29788127 DOI: 10.1093/ibd/izy150] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 24.0] [Reference Citation Analysis]
247 Mushtaq K, Khan Z, Aziz M, Alyousif ZA, Siddiqui N, Khan MA, Nawras A. Trends and outcomes of fungal infections in hospitalized patients of inflammatory bowel disease: a nationwide analysis. Transl Gastroenterol Hepatol 2020;5:35. [PMID: 32632386 DOI: 10.21037/tgh.2019.10.14] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
248 Lee SH, Bajracharya R, Min JY, Han JW, Park BJ, Han HK. Strategic Approaches for Colon Targeted Drug Delivery: An Overview of Recent Advancements. Pharmaceutics 2020;12:E68. [PMID: 31952340 DOI: 10.3390/pharmaceutics12010068] [Cited by in Crossref: 36] [Cited by in F6Publishing: 22] [Article Influence: 36.0] [Reference Citation Analysis]
249 López-Sanromán A, Esplugues JV, Domènech E. Pharmacology and safety of tofacitinib in ulcerative colitis. Gastroenterol Hepatol 2021;44:39-48. [PMID: 32829958 DOI: 10.1016/j.gastrohep.2020.04.012] [Reference Citation Analysis]
250 Nigam GB, Bhandare AP, Antoniou GA, Limdi JK. Systematic review and meta-analysis of dermatological reactions in patients with inflammatory bowel disease treated with anti-tumour necrosis factor therapy. Eur J Gastroenterol Hepatol 2021;33:346-57. [PMID: 32889976 DOI: 10.1097/MEG.0000000000001917] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
251 Andrisani G, Armuzzi A, Marzo M, Felice C, Pugliese D, Papa A, Guidi L. What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients? World J Gastrointest Pharmacol Ther 2016;7:387-96. [PMID: 27602239 DOI: 10.4292/wjgpt.v7.i3.387] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
252 Adegbola SO, Sahnan K, Warusavitarne J, Hart A, Tozer P. Anti-TNF Therapy in Crohn's Disease. Int J Mol Sci 2018;19:E2244. [PMID: 30065229 DOI: 10.3390/ijms19082244] [Cited by in Crossref: 80] [Cited by in F6Publishing: 58] [Article Influence: 26.7] [Reference Citation Analysis]
253 Degasperi E, Caprioli F, El Sherif O, Back D, Colombo M, Aghemo A. Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection. Expert Rev Gastroenterol Hepatol. 2016;10:1373-1383. [PMID: 27718758 DOI: 10.1080/17474124.2016.1246181] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
254 Marín-Jiménez I, Zabana Y, Rodríguez-Lago I, Marín L, Barreiro-de Acosta M, Esteve M; en representación de GETEII y GETECCU. COVID-19 and inflammatory bowel disease: questions arising from patient care and follow-up during the initial phase of the pandemic (February-April 2020). Gastroenterol Hepatol 2020;43:408-13. [PMID: 32419715 DOI: 10.1016/j.gastrohep.2020.05.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
255 Riestra S, Taxonera C, Zabana Y, Carpio D, Beltrán B, Mañosa M, Gutiérrez A, Barreiro-de Acosta M. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on screening and treatment of tuberculosis infection in patients with inflammatory bowel disease. Gastroenterol Hepatol 2021;44:51-66. [PMID: 32828562 DOI: 10.1016/j.gastrohep.2020.04.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
256 Gong J, Meyerowitz EA, Isidro RA, Kaye KM. Primary cytomegalovirus infection with invasive disease in a patient with inflammatory bowel disease. BMJ Case Rep 2019;12:e230056. [PMID: 31570344 DOI: 10.1136/bcr-2019-230056] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
257 Yerushalmy-Feler A, Padlipsky J, Cohen S. Diagnosis and Management of CMV Colitis. Curr Infect Dis Rep. 2019;21:5. [PMID: 30771028 DOI: 10.1007/s11908-019-0664-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
258 Stamatiades GA, Ioannou P, Petrikkos G, Tsioutis C. Fungal infections in patients with inflammatory bowel disease: A systematic review. Mycoses 2018;61:366-76. [PMID: 29453860 DOI: 10.1111/myc.12753] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
259 Ordás I, Domènech E, Mañosa M, García-Sánchez V, Iglesias-Flores E, Peñalva M, Cañas-Ventura A, Merino O, Fernández-Bañares F, Gomollón F, Vera M, Gutiérrez A, Garcia-Planella E, Chaparro M, Aguas M, Gento E, Muñoz F, Aguirresarobe M, Muñoz C, Fernández L, Calvet X, Jiménez CE, Montoro MA, Mir A, De Castro ML, García-Sepulcre MF, Bermejo F, Panés J, Esteve M. Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989-2013): A Nationwide Multicenter Study. Am J Gastroenterol 2017;112:1709-18. [PMID: 28675163 DOI: 10.1038/ajg.2017.180] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 9.8] [Reference Citation Analysis]
260 Chen D, Luo S, Ben Q, Lu L, Wan X, Wu J. Prevalence of hepatitis B and C and factors for infection and nonimmune in inflammatory bowel disease patients in China. Eur J Gastroenterol Hepatol. 2017;29:509-515. [PMID: 28350740 DOI: 10.1097/meg.0000000000000838] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
261 Cotter TG, Gathaiya N, Catania J, Loftus EV Jr, Tremaine WJ, Baddour LM, Harmsen WS, Zinsmeister AR, Sandborn WJ, Limper AH, Pardi DS. Low Risk of Pneumonia From Pneumocystis jirovecii Infection in Patients With Inflammatory Bowel Disease Receiving Immune Suppression. Clin Gastroenterol Hepatol 2017;15:850-6. [PMID: 28013116 DOI: 10.1016/j.cgh.2016.11.037] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
262 Cheon JH. Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease: Biologics therapy in East Asia. Journal of Gastroenterology and Hepatology 2017;32:769-77. [DOI: 10.1111/jgh.13612] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
263 Queiroz NSF, Barros LL, Azevedo MFC, Oba J, Sobrado CW, Carlos AS, Milani LR, Sipahi AM, Damião AOMC. Management of inflammatory bowel disease patients in the COVID-19 pandemic era: a Brazilian tertiary referral center guidance. Clinics (Sao Paulo) 2020;75:e1909. [PMID: 32321117 DOI: 10.6061/clinics/2020/e1909] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 15.0] [Reference Citation Analysis]
264 Cappello M, Morreale GC. The Role of Laboratory Tests in Crohn's Disease. Clin Med Insights Gastroenterol. 2016;9:51-62. [PMID: 27656094 DOI: 10.4137/cgast.s38203] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 2.4] [Reference Citation Analysis]
265 Byun JM, Lee CK, Rhee SY, Kim HJ, Kim JW, Shim JJ, Jang JY. The risk of tuberculosis in Korean patients with inflammatory bowel disease receiving tumor necrosis factor-α blockers. J Korean Med Sci 2015;30:173-9. [PMID: 25653489 DOI: 10.3346/jkms.2015.30.2.173] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
266 Taxonera C, Ponferrada Á, Bermejo F, Riestra S, Saro C, Martín-Arranz MD, Cabriada JL, Barreiro-de Acosta M, de Castro ML, López-Serrano P, Barrio J, Suarez C, Iglesias E, Argüelles-Arias F, Ferrer I, Marín-Jiménez I, Hernández-Camba A, Bastida G, Van Domselaar M, Martínez-Montiel P, Olivares D, Alba C, Gisbert JP; SEGURTB study group from GETECCU. Early Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease. J Crohns Colitis 2017;11:792-800. [PMID: 28333182 DOI: 10.1093/ecco-jcc/jjx022] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
267 Liu C, Ji S, Ding Y, Zhou L, Liu X, Li W. Cytomegalovirus infection and steroid-refractory inflammatory bowel disease: possible relationship from an updated meta-analysis. Ir J Med Sci 2018;187:935-42. [DOI: 10.1007/s11845-018-1752-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
268 Huguet JM, Iborra M, Bosca-Watts MM, Maroto N, Gil R, Cortes X, Hervás D, Paredes JM. Inflammatory bowel disease in patients over the age of 70 y. Does the disease duration influence its behavior? Scand J Gastroenterol 2018;53:1079-84. [PMID: 30189153 DOI: 10.1080/00365521.2018.1501603] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
269 Inflammatory Bowel Disease Group, Chinese Society of Gastroenterology, Chinese Medical Association. Evidence-based consensus on opportunistic infections in inflammatory bowel disease (republication). Intest Res 2018;16:178-93. [PMID: 29743831 DOI: 10.5217/ir.2018.16.2.178] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 3.7] [Reference Citation Analysis]
270 Yoshida M, Takeuchi I, Shoji K, Miyairi I, Arai K. Bacillus Calmette-Guérin Cervical Lymphadenitis in a 6-Year-Old Boy on Infliximab for Inflammatory Bowel Disease. Pediatr Infect Dis J 2020;39:e242-4. [PMID: 32345827 DOI: 10.1097/INF.0000000000002712] [Reference Citation Analysis]
271 Bezzio C, Saibeni S, Variola A, Allocca M, Massari A, Gerardi V, Casini V, Ricci C, Zingone F, Amato A, Caprioli F, Lenti MV, Viganò C, Ascolani M, Bossa F, Castiglione F, Cortelezzi C, Grossi L, Milla M, Morganti D, Pastorelli L, Ribaldone DG, Sartini A, Soriano A, Manes G, Danese S, Fantini MC, Armuzzi A, Daperno M, Fiorino G; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut 2020;69:1213-7. [PMID: 32354990 DOI: 10.1136/gutjnl-2020-321411] [Cited by in Crossref: 154] [Cited by in F6Publishing: 130] [Article Influence: 154.0] [Reference Citation Analysis]
272 Ahmed T, Brown F, Ahmed R, Shah A, Whitehead S, Steed H, Brookes MJ. Letter: impact of Epstein-Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease. Aliment Pharmacol Ther 2019;49:476-7. [DOI: 10.1111/apt.15104] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
273 Nørgård BM, Nielsen J, Knudsen T, Nielsen RG, Larsen MD, Jølving LR, Kjeldsen J. Hospitalization for COVID-19 in patients treated with selected immunosuppressant and immunomodulating agents, compared to the general population: A Danish cohort study. Br J Clin Pharmacol 2021;87:2111-20. [PMID: 33098713 DOI: 10.1111/bcp.14622] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
274 Cohen S, Martinez-vinson C, Aloi M, Turner D, Assa A, de Ridder L, Wolters VM, de Meij T, Alvisi P, Bronsky J, Kopylov U. Cytomegalovirus Infection in Pediatric Severe Ulcerative Colitis—A Multicenter Study from the Pediatric Inflammatory Bowel Disease Porto Group of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. Pediatric Infectious Disease Journal 2018;37:197-201. [DOI: 10.1097/inf.0000000000001724] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
275 Dembiński Ł, Krzesiek E, Klincewicz B, Grzybowska-Chlebowczyk U, Demkow U, Banaszkiewicz A, Radzikowski A. Immunogenicity of Diphtheria Booster Vaccination in Adolescents With Inflammatory Bowel Disease. Pediatr Infect Dis J 2020;39:244-6. [PMID: 32032309 DOI: 10.1097/INF.0000000000002547] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
276 Hashash JG, Abou Fadel C, Hosni M, Hassoun L, Kanafani Z, Regueiro MD. Approach to Latent Tuberculosis Infection Screening Before Biologic Therapy in IBD Patients: PPD or IGRA? Inflammatory Bowel Diseases 2020;26:1315-8. [DOI: 10.1093/ibd/izaa139] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
277 Segal JP, Htet HMT, Limdi J, Hayee B. How to manage IBD in the 'elderly'. Frontline Gastroenterol 2020;11:468-77. [PMID: 33101625 DOI: 10.1136/flgastro-2019-101218] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
278 Ciccocioppo R, Racca F, Paolucci S, Campanini G, Pozzi L, Betti E, Riboni R, Vanoli A, Baldanti F, Corazza GR. Human cytomegalovirus and Epstein-Barr virus infection in inflammatory bowel disease: need for mucosal viral load measurement. World J Gastroenterol 2015;21:1915-26. [PMID: 25684960 DOI: 10.3748/wjg.v21.i6.1915] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 37] [Article Influence: 7.2] [Reference Citation Analysis]
279 Ganzenmueller T, Kluba J, Becker JU, Bachmann O, Heim A. Detection of cytomegalovirus (CMV) by real-time PCR in fecal samples for the non-invasive diagnosis of CMV intestinal disease. J Clin Virol. 2014;61:517-522. [PMID: 25453330 DOI: 10.1016/j.jcv.2014.10.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
280 Chadwick DR, Sayeed L, Rose M, Budd E, Mohammed M, Harrison S, Azad J, Maddox J. Adherence to guidelines across different specialties to prevent infections in patients undergoing immunosuppressive therapies. BMC Infect Dis 2020;20:359. [PMID: 32434480 DOI: 10.1186/s12879-020-05082-8] [Reference Citation Analysis]
281 Long MD, Gulati A, Wohl D, Herfarth H. Immunizations in Pediatric and Adult Patients with Inflammatory Bowel Disease: A Practical Case-based Approach. Inflamm Bowel Dis 2015;21:1993-2003. [PMID: 25966839 DOI: 10.1097/MIB.0000000000000395] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
282 Chen J, Andrews JM, Kariyawasam V, Moran N, Gounder P, Collins G, Walsh AJ, Connor S, Lee TWT, Koh CE, Chang J, Paramsothy S, Tattersall S, Lemberg DA, Radford-smith G, Lawrance IC, Mclachlan A, Moore GT, Corte C, Katelaris P, Leong RW; IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group. Review article: acute severe ulcerative colitis - evidence-based consensus statements. Aliment Pharmacol Ther 2016;44:127-44. [DOI: 10.1111/apt.13670] [Cited by in Crossref: 48] [Cited by in F6Publishing: 32] [Article Influence: 9.6] [Reference Citation Analysis]
283 Launay O, Abitbol V, Krivine A, Slama LB, Bourreille A, Dupas JL, Hébuterne X, Savoye G, Deplanque D, Bouhnik Y, Pelletier AL, Galtier F, Laharie D, Nachury M, Zerbib F, Allez M, Bommelaer G, Duclos B, Lucht F, Gougeon ML, Tartour E, Rozenberg F, Hanslik T, Beaugerie L, Carrat F; MICIVAX Study Group. Immunogenicity and Safety of Influenza Vaccine in Inflammatory Bowel Disease Patients Treated or not with Immunomodulators and/or Biologics: A Two-year Prospective Study. J Crohns Colitis 2015;9:1096-107. [PMID: 26351392 DOI: 10.1093/ecco-jcc/jjv152] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
284 Jeuring SF, van den Heuvel TR, Zeegers MP, Hameeteman WH, Romberg-Camps MJ, Oostenbrug LE, Masclee AA, Jonkers DM, Pierik MJ. Epidemiology and Long-term Outcome of Inflammatory Bowel Disease Diagnosed at Elderly Age-An Increasing Distinct Entity? Inflamm Bowel Dis 2016;22:1425-34. [PMID: 26933752 DOI: 10.1097/MIB.0000000000000738] [Cited by in Crossref: 70] [Cited by in F6Publishing: 22] [Article Influence: 23.3] [Reference Citation Analysis]
285 Banerjee R, Pal P, Mak JWY, Ng SC. Challenges in the diagnosis and management of inflammatory bowel disease in resource-limited settings in Asia. Lancet Gastroenterol Hepatol 2020;5:1076-88. [PMID: 33181087 DOI: 10.1016/S2468-1253(20)30299-5] [Cited by in Crossref: 6] [Article Influence: 6.0] [Reference Citation Analysis]
286 Kantsø B, Halkjær SI, Thomsen OØ, Belard E, Gottschalck IB, Jørgensen CS, Krogfelt KA, Slotved H, Ingels H, Petersen AM. Immunosuppressive drugs impairs antibody response of the polysaccharide and conjugated pneumococcal vaccines in patients with Crohn's disease. Vaccine 2015;33:5464-9. [DOI: 10.1016/j.vaccine.2015.08.011] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 4.7] [Reference Citation Analysis]
287 Fréling E, Baumann C, Cuny J, Bigard M, Schmutz J, Barbaud A, Peyrin-biroulet L. Cumulative Incidence of, Risk Factors for, and Outcome of Dermatological Complications of Anti-TNF Therapy in Inflammatory Bowel Disease: A 14-Year Experience. American Journal of Gastroenterology 2015;110:1186-96. [DOI: 10.1038/ajg.2015.205] [Cited by in Crossref: 72] [Cited by in F6Publishing: 56] [Article Influence: 12.0] [Reference Citation Analysis]
288 van Rheenen PF, Aloi M, Assa A, Bronsky J, Escher JC, Fagerberg UL, Gasparetto M, Gerasimidis K, Griffiths A, Henderson P, Koletzko S, Kolho KL, Levine A, van Limbergen J, Martin de Carpi FJ, Navas-López VM, Oliva S, de Ridder L, Russell RK, Shouval D, Spinelli A, Turner D, Wilson D, Wine E, Ruemmele FM. The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update. J Crohns Colitis 2020:jjaa161. [PMID: 33026087 DOI: 10.1093/ecco-jcc/jjaa161] [Cited by in Crossref: 33] [Cited by in F6Publishing: 21] [Article Influence: 33.0] [Reference Citation Analysis]
289 Lobatón T, Domènech E. Bacterial Intestinal Superinfections in Inflammatory Bowel Diseases Beyond Clostridum difficile. Inflamm Bowel Dis 2016;22:1755-62. [PMID: 27104824 DOI: 10.1097/MIB.0000000000000788] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
290 Craviotto V, Furfaro F, Loy L, Zilli A, Peyrin-Biroulet L, Fiorino G, Danese S, Allocca M. Viral infections in inflammatory bowel disease: Tips and tricks for correct management. World J Gastroenterol 2021;27:4276-97. [PMID: 34366605 DOI: 10.3748/wjg.v27.i27.4276] [Reference Citation Analysis]
291 Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V, Calabrese E, Baumgart DC, Bettenworth D, Borralho Nunes P, Burisch J, Castiglione F, Eliakim R, Ellul P, González-Lama Y, Gordon H, Halligan S, Katsanos K, Kopylov U, Kotze PG, Krustinš E, Laghi A, Limdi JK, Rieder F, Rimola J, Taylor SA, Tolan D, van Rheenen P, Verstockt B, Stoker J; European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR]. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis 2019;13:144-64. [PMID: 30137275 DOI: 10.1093/ecco-jcc/jjy113] [Cited by in Crossref: 313] [Cited by in F6Publishing: 238] [Article Influence: 156.5] [Reference Citation Analysis]
292 Alvisi P, Dipasquale V, Barabino A, Martellossi S, Miele E, Lionetti P, Lombardi G, Cucchiara S, Torre G, Romano C. Infections and malignancies risks related to TNF-α-blocking agents in pediatric inflammatory bowel diseases. Expert Rev Gastroenterol Hepatol 2019;13:957-61. [PMID: 31490707 DOI: 10.1080/17474124.2019.1663173] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
293 Dobsch P, Michels B, Müller-Schilling M, Kandulski A. [Therapeutic regimens using monoclonal antibodies in gastroenterology]. Internist (Berl) 2019;60:1043-58. [PMID: 31501913 DOI: 10.1007/s00108-019-00682-2] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
294 Maconi G, Bosetti C, De Monti A, Boyapati RK, Shelton E, Piazza N, Carvalhas Gabrielli AM, Lenti MV, Bezzio C, Ricci C, Greco S, Romeo S, Giangregorio F, Gridavilla D, Tagliani F, Massari A, Pastorelli L, Di Sabatino A, Saibeni S, Alicante S, Ferretti F, Rizzardini G, Galli M, Ardizzone S. Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population. Dig Liver Dis. 2021;53:263-270. [PMID: 33483259 DOI: 10.1016/j.dld.2020.12.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
295 Sheriff MZ, Mansoor E, Luther J, Ananthakrishnan AN, Abou Saleh M, Ho E, Briggs FBS, Dave M. Opportunistic Infections Are More Prevalent in Crohn's Disease and Ulcerative Colitis: A Large Population-Based Study. Inflamm Bowel Dis 2020;26:291-300. [PMID: 31314891 DOI: 10.1093/ibd/izz147] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
296 Woziwodzka A, Rybicka M, Sznarkowska A, Romanowski T, Dręczewski M, Stalke P, Bielawski KP. TNF-α polymorphisms affect persistence and progression of HBV infection. Mol Genet Genomic Med 2019;7:e00935. [PMID: 31441603 DOI: 10.1002/mgg3.935] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
297 Magro F, Rahier JF, Abreu C, MacMahon E, Hart A, van der Woude CJ, Gordon H, Adamina M, Viget N, Vavricka S, Kucharzik T, Leone S, Siegmund B, Danese S, Peyrin-Biroulet L. Inflammatory Bowel Disease Management During the COVID-19 Outbreak: The Ten Do's and Don'ts from the ECCO-COVID Taskforce. J Crohns Colitis. 2020;14:S798-S806. [PMID: 32722754 DOI: 10.1093/ecco-jcc/jjaa160] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 27.0] [Reference Citation Analysis]
298 Righi E, Gallo T, Azzini AM, Mazzaferri F, Cordioli M, Merighi M, Tacconelli E. A Review of Vaccinations in Adult Patients with Secondary Immunodeficiency. Infect Dis Ther 2021;10:637-61. [PMID: 33687662 DOI: 10.1007/s40121-021-00404-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
299 Magrì S, Chessa L, Demurtas M, Cabras F, Mocci G. Review article: safety of new biologic agents for inflammatory bowel disease in the liver. Eur J Gastroenterol Hepatol 2021;33:623-30. [PMID: 33470695 DOI: 10.1097/MEG.0000000000002076] [Reference Citation Analysis]
300 Abitbol Y, Laharie D, Cosnes J, Allez M, Nancey S, Amiot A, Aubourg A, Fumery M, Altwegg R, Michetti P, Chanteloup E, Seksik P, Baudry C, Flamant M, Bouguen G, Stefanescu C, Bourrier A, Bommelaer G, Dib N, Bigard MA, Viennot S, Hébuterne X, Gornet JM, Marteau P, Bouhnik Y, Abitbol V, Nahon S; GETAID. Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort. J Crohns Colitis 2016;10:1179-85. [PMID: 27402916 DOI: 10.1093/ecco-jcc/jjw129] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 7.6] [Reference Citation Analysis]
301 Tarazona B, Díaz-Menéndez M, Mato Chaín G. International travelers receiving pharmacological immunosuppression: Challenges and opportunities. Med Clin (Barc) 2018;150:233-9. [PMID: 29096964 DOI: 10.1016/j.medcli.2017.08.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
302 Choi CH, Moon W, Kim YS, Kim ES, Lee BI, Jung Y, Yoon YS, Lee H, Park DI, Han DS; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Second Korean guidelines for the management of ulcerative colitis. Intest Res. 2017;15:7-37. [PMID: 28239313 DOI: 10.5217/ir.2017.15.1.7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 24] [Article Influence: 9.3] [Reference Citation Analysis]
303 Tarazona B, Díaz-menéndez M, Mato Chaín G. International travelers receiving pharmacological immunosuppression: Challenges and opportunities. Medicina Clínica (English Edition) 2018;150:233-9. [DOI: 10.1016/j.medcle.2018.01.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
304 Desalermos AP, Farraye FA, Wasan SK. Vaccinating the inflammatory bowel disease patient. Expert Rev Gastroenterol Hepatol 2015;9:91-102. [PMID: 25160668 DOI: 10.1586/17474124.2014.934672] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
305 Hernández M, González-Lama Y, Ramos A, Martínez-Ruiz R, Calvo M, Matallana V, Vera MI, Suarez C, Blázquez I, Abreu L. Visceral leishmaniasis as an unusual infectious complication in a patient with Crohn's disease treated with infliximab. Gastroenterol Hepatol 2015;38:411-2. [PMID: 25443540 DOI: 10.1016/j.gastrohep.2014.08.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
306 Cagol L, Seitel T, Ehrenberg S, Frivolt K, Krahl A, Lainka E, Gerner P, Lenhartz H, Vermehren J, Radke M, Trenkel S, Mayer B, Koletzko S, Debatin K, Mertens T, Posovszky C. Vaccination rate and immunity of children and adolescents with inflammatory bowel disease or autoimmune hepatitis in Germany. Vaccine 2020;38:1810-7. [DOI: 10.1016/j.vaccine.2019.12.024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
307 Pagnini C, Arseneau KO, Cominelli F. Safety considerations when using anti-TNFα therapy to treat Crohn's disease. Expert Opin Drug Saf 2015;14:31-44. [PMID: 25400161 DOI: 10.1517/14740338.2015.976610] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
308 Greveson K. Developing an evidence-based online travel resource for inflammatory bowel disease. Gastrointestinal Nursing 2014;12:13-20. [DOI: 10.12968/gasn.2014.12.10.13] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
309 Ardesia M, Costantino G, Mondello P, Alibrandi A, Fries W. Serology of Viral Infections and Tuberculosis Screening in an IBD Population Referred to a Tertiary Centre of Southern Italy. Gastroenterol Res Pract 2017;2017:4139656. [PMID: 29075289 DOI: 10.1155/2017/4139656] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
310 Desideri F, Pagnini C, Marignani M. Administration of Two Anti-TNF  Agents in an Ulcerative Colitis Patient with HBV-related Cirrhosis. Journal of Crohn's and Colitis 2015;9:430-1. [DOI: 10.1093/ecco-jcc/jjv045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
311 Arora A, Anand AC, Kumar A, Singh SP, Aggarwal R, Dhiman RK, Aggarwal S, Alam S, Bhaumik P, Dixit VK, Goel A, Goswami B, Kumar A, Kumar M, Madan K, Murugan N, Nagral A, Puri AS, Rao PN, Saraf N, Saraswat VA, Sehgal S, Sharma P, Shenoy KT, Wadhawan M; Members of the INASL taskforce on Hepatitis B. INASL Guidelines on Management of Hepatitis B Virus Infection in Patients receiving Chemotherapy, Biologicals, Immunosupressants, or Corticosteroids. J Clin Exp Hepatol 2018;8:403-31. [PMID: 30568345 DOI: 10.1016/j.jceh.2018.06.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
312 Marín AC, Gisbert JP, Chaparro M. Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease. World J Gastroenterol 2015;21:11273-81. [PMID: 26527572 DOI: 10.3748/wjg.v21.i40.11273] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
313 Chu Y, Jiang MZ, Xu B, Wang WJ, Chen D, Li XW, Zhang YJ, Liang J. Specific changes of enteric mycobiota and virome in inflammatory bowel disease. J Dig Dis. 2018;19:2-7. [PMID: 29266753 DOI: 10.1111/1751-2980.12570] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
314 Sarid O, Slonim-nevo V, Schwartz D, Friger M, Sergienko R, Pereg A, Vardi H, Chernin E, Singer T, Greenberg D, Odes S; on behalf of the Israel IBD Research Nucleus (IIRN). Differing Relationship of Psycho-Social Variables with Active Ulcerative Colitis or Crohn’s Disease. Int J Behav Med 2018;25:341-50. [DOI: 10.1007/s12529-018-9712-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
315 Manser CN, Maillard MH, Rogler G, Schreiner P, Rieder F, Bühler S; on behalf of Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology. Vaccination in Patients with Inflammatory Bowel Diseases. Digestion 2020;101 Suppl 1:58-68. [PMID: 31968344 DOI: 10.1159/000503253] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
316 Calvet X, Carpio D, Rodríguez-Lago I, García-Vicuña R, Barreiro-de-Acosta M, Juanola X, Aguas M, Castillo C, Gratacós J. Risk of infection associated with Janus Kinase (JAK) inhibitors and biological therapies in inflammatory intestinal disease and rheumatoid arthritis. Prevention strategies. Gastroenterol Hepatol 2021:S0210-5705(21)00056-X. [PMID: 33640469 DOI: 10.1016/j.gastrohep.2021.01.007] [Reference Citation Analysis]
317 Gargallo-Puyuelo CJ, Laredo V, Gomollón F. Thiopurines in Inflammatory Bowel Disease. How to Optimize Thiopurines in the Biologic Era? Front Med (Lausanne) 2021;8:681907. [PMID: 34336887 DOI: 10.3389/fmed.2021.681907] [Reference Citation Analysis]
318 Santella C, Bitton A, Filliter C, Bessissow T, Vutcovici M, Lakatos PL, Brassard P. Anti-TNF Therapy and the Risk of Herpes Zoster Among Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis 2021:izab092. [PMID: 33999136 DOI: 10.1093/ibd/izab092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
319 Farshidpour M, Charabaty A, Mattar MC. Improving immunization strategies in patients with inflammatory bowel disease. Ann Gastroenterol 2019;32:247-56. [PMID: 31040621 DOI: 10.20524/aog.2019.0351] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
320 Mavropoulou E, Ternes K, Mechie NC, Bremer SCB, Kunsch S, Ellenrieder V, Neesse A, Amanzada A. Cytomegalovirus colitis in inflammatory bowel disease and after haematopoietic stem cell transplantation: diagnostic accuracy, predictors, risk factors and disease outcome. BMJ Open Gastroenterol 2019;6:e000258. [PMID: 30899538 DOI: 10.1136/bmjgast-2018-000258] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
321 Annese V, Duricova D, Gower-rousseau C, Jess T, Langholz E. Impact of New Treatments on Hospitalisation, Surgery, Infection, and Mortality in IBD: a Focus Paper by the Epidemiology Committee of ECCO. ECCOJC 2016;10:216-25. [DOI: 10.1093/ecco-jcc/jjv190] [Cited by in Crossref: 70] [Cited by in F6Publishing: 53] [Article Influence: 11.7] [Reference Citation Analysis]
322 Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, Adamina M, Armuzzi A, Bachmann O, Bager P, Biancone L, Bokemeyer B, Bossuyt P, Burisch J, Collins P, El-hussuna A, Ellul P, Frei-lanter C, Furfaro F, Gingert C, Gionchetti P, Gomollon F, González-lorenzo M, Gordon H, Hlavaty T, Juillerat P, Katsanos K, Kopylov U, Krustins E, Lytras T, Maaser C, Magro F, Kenneth Marshall J, Myrelid P, Pellino G, Rosa I, Sabino J, Savarino E, Spinelli A, Stassen L, Uzzan M, Vavricka S, Verstockt B, Warusavitarne J, Zmora O, Fiorino G. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. Journal of Crohn's and Colitis 2020;14:4-22. [DOI: 10.1093/ecco-jcc/jjz180] [Cited by in Crossref: 184] [Cited by in F6Publishing: 125] [Article Influence: 92.0] [Reference Citation Analysis]
323 Kirchgesner J, Lemaitre M, Rudnichi A, Racine A, Zureik M, Carbonnel F, Dray-spira R. Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014. Aliment Pharmacol Ther 2017;45:37-49. [DOI: 10.1111/apt.13835] [Cited by in Crossref: 46] [Cited by in F6Publishing: 35] [Article Influence: 9.2] [Reference Citation Analysis]
324 Argollo M, Gilardi D, Peyrin-Biroulet C, Chabot JF, Peyrin-Biroulet L, Danese S. Comorbidities in inflammatory bowel disease: a call for action. Lancet Gastroenterol Hepatol 2019;4:643-54. [PMID: 31171484 DOI: 10.1016/S2468-1253(19)30173-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
325 Waszczuk K, Waszczuk E, Mulak A, Szenborn L, Paradowski L. A 'cocoon immunization strategy' among patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2015;27:249-53. [PMID: 25569568 DOI: 10.1097/MEG.0000000000000280] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 2.2] [Reference Citation Analysis]
326 Abid H, Atmani I, Lahmidani N, El Yousfi M, Benajah DA, Ibrahimi SA, El Abkari M. [Chronic inflammatory bowel diseases: what happens when SARS-CoV-2 occurs? Preliminary results from a study conducted at the Hassan II University Teaching Hospital in Fes, Morocco (a case report)]. Pan Afr Med J 2021;38:382. [PMID: 34381526 DOI: 10.11604/pamj.2021.38.382.27235] [Reference Citation Analysis]
327 Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, Veres G, Aloi M, Strisciuglio C, Braegger CP, Assa A, Romano C, Hussey S, Stanton M, Pakarinen M, de Ridder L, Katsanos KH, Croft N, Navas-López VM, Wilson DC, Lawrence S, Russell RK. Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis-An Evidence-based Consensus Guideline From the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:292-310. [PMID: 30044358 DOI: 10.1097/MPG.0000000000002036] [Cited by in Crossref: 64] [Cited by in F6Publishing: 19] [Article Influence: 32.0] [Reference Citation Analysis]
328 Jiang HY, Wang SY, Deng M, Li YC, Ling ZX, Shao L, Ruan B. Immune response to hepatitis B vaccination among people with inflammatory bowel diseases: A systematic review and meta-analysis. Vaccine. 2017;35:2633-2641. [PMID: 28404358 DOI: 10.1016/j.vaccine.2017.03.080] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
329 Arihiro S, Nakashima A, Matsuoka M, Suto S, Uchiyama K, Kato T, Mitobe J, Komoike N, Itagaki M, Miyakawa Y, Koido S, Hokari A, Saruta M, Tajiri H, Matsuura T, Urashima M. Randomized Trial of Vitamin D Supplementation to Prevent Seasonal Influenza and Upper Respiratory Infection in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis 2019;25:1088-95. [PMID: 30601999 DOI: 10.1093/ibd/izy346] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 32.0] [Reference Citation Analysis]
330 Kohl SE, Barnett ED. What do we know about travel for children with special health care needs? A review of the literature. Travel Med Infect Dis 2020;34:101438. [PMID: 31233860 DOI: 10.1016/j.tmaid.2019.06.009] [Reference Citation Analysis]
331 Dragoni G, Le Grazie M, Orlandini B, Rogai F. Golimumab in inflammatory bowel diseases: present and future scenarios. Clin J Gastroenterol 2019;12:1-9. [DOI: 10.1007/s12328-018-0906-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
332 Clos-parals A, Rodríguez-martínez P, Cañete F, Mañosa M, Ruiz-cerulla A, José Paúles M, Llaó J, Gordillo J, Fumagalli C, Garcia-planella E, Ojanguren I, Cabré E, Guardiola J, Domènech E. Prognostic Value of the Burden of Cytomegalovirus Colonic Reactivation Evaluated by Immunohistochemical Staining in Patients with Active Ulcerative Colitis. Journal of Crohn's and Colitis 2019;13:385-8. [DOI: 10.1093/ecco-jcc/jjy173] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
333 Thi AA, Abbara A, Bouri S, Collin SM, Wolfson P, Owen L, Buell KG, John L, Hart AL. Challenges in screening for latent tuberculosis in inflammatory bowel disease prior to biologic treatment: a UK cohort study. Frontline Gastroenterol 2018;9:234-40. [PMID: 30046428 DOI: 10.1136/flgastro-2017-100951] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
334 Zidar N, Ferkolj I, Tepeš K, Štabuc B, Kojc N, Uršič T, Petrovec M. Diagnosing cytomegalovirus in patients with inflammatory bowel disease--by immunohistochemistry or polymerase chain reaction? Virchows Arch 2015;466:533-9. [PMID: 25701481 DOI: 10.1007/s00428-015-1741-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
335 Esposito S, Antoniol G, Labate M, Passadore L, Alvisi P, Daccò V, Ghizzi C, Colombo C, Principi N. Vaccines in Children with Inflammatory Bowel Disease: Brief Review. Vaccines (Basel) 2021;9:487. [PMID: 34064576 DOI: 10.3390/vaccines9050487] [Reference Citation Analysis]
336 Bossa F, Carparelli S, Latiano A, Palmieri O, Tavano F, Panza A, Pastore M, Marseglia A, D'Altilia M, Latiano T, Corritore G, Martino G, Nardella M, Guerra M, Terracciano F, Sacco M, Perri F, Andriulli A. Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs. Dig Liver Dis. 2021;53:277-282. [PMID: 33423942 DOI: 10.1016/j.dld.2020.12.120] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
337 Shrestha MP, Taleban S. Management of Ulcerative Colitis in the Elderly. Drugs Aging 2019;36:13-27. [DOI: 10.1007/s40266-018-0611-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
338 Moum KM, Moum B, Opheim R. Patients with inflammatory bowel disease on immunosuppressive drugs: perspectives' on COVID-19 and health care service during the pandemic. Scand J Gastroenterol 2021;56:545-51. [PMID: 33771086 DOI: 10.1080/00365521.2021.1901308] [Reference Citation Analysis]
339 Tandon P, McCurdy JD, Smyrk TC. Is Standard Histology Sufficient to Detect Cytomegalovirus Reactivation in Inflammatory Bowel Disease? Am J Clin Pathol 2017;148:459-60. [PMID: 29106458 DOI: 10.1093/ajcp/aqx045] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
340 Ben-horin S, Mao R, Qiu Y, Chen M. Discontinuation of Biological Treatments in Inflammatory Bowel Disease: A Concise Pragmatic Review. Journal of Clinical Gastroenterology 2018;52:6-12. [DOI: 10.1097/mcg.0000000000000938] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
341 Troncone E, Monteleone G. The safety of non-biological treatments in Ulcerative Colitis. Expert Opin Drug Saf 2017;16:779-89. [PMID: 28608717 DOI: 10.1080/14740338.2017.1340936] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
342 Sedano R, Quera R, Simian D, Yarur AJ. An approach to acute severe ulcerative colitis. Expert Rev Gastroenterol Hepatol 2019;13:943-55. [PMID: 31648574 DOI: 10.1080/17474124.2019.1681974] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
343 Tosca J, Garcia N, Pascual I, Bosca-Watts MM, Anton R, Sanahuja A, Mas P, Mora F, Minguez M. Clinical assessment of risk factors for infection in inflammatory bowel disease patients. Int J Colorectal Dis 2020;35:491-500. [PMID: 31915983 DOI: 10.1007/s00384-019-03501-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
344 Park DI, Hisamatsu T, Chen M, Ng SC, Ooi CJ, Wei SC, Banerjee R, Hilmi IN, Jeen YT, Han DS, Kim HJ, Ran Z, Wu K, Qian J, Hu PJ, Matsuoka K, Andoh A, Suzuki Y, Sugano K, Watanabe M, Hibi T, Puri AS, Yang SK. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment. Intest Res 2018;16:4-16. [PMID: 29422793 DOI: 10.5217/ir.2018.16.1.4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
345 Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, Makharia GK, Pisespongsa P, Chen MH, Ran ZH, Ye BD, Park DI, Ling KL, Ong D, Ahuja V, Goh KL, Sollano J, Lim WC, Leung WK, Ali RAR, Wu DC, Ong E, Mustaffa N, Limsrivilai J, Hisamatsu T, Yang SK, Ouyang Q, Geary R, De Silva JH, Rerknimitr R, Simadibrata M, Abdullah M, Leong RWL; Asia-Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn's and Colitis. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. J Gastroenterol Hepatol 2019;34:1296-315. [PMID: 30848854 DOI: 10.1111/jgh.14648] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 7.5] [Reference Citation Analysis]
346 Zagórowicz E, Bugajski M, Wieszczy P, Pietrzak A, Magdziak A, Mróz A. Cytomegalovirus Infection in Ulcerative Colitis is Related to Severe Inflammation and a High Count of Cytomegalovirus-positive Cells in Biopsy Is a Risk Factor for Colectomy. ECCOJC 2016;10:1205-11. [DOI: 10.1093/ecco-jcc/jjw071] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 5.2] [Reference Citation Analysis]
347 Albuquerque A, Cappello C, Cuming T, De Masi A, Bowring J, Rosenthal AN, Nathan •M. Anal High-Grade Squamous Intraepithelial Lesions in Pharmacologically Immunocompromised Patients Followed in a Referral Center. Diseases of the Colon & Rectum 2018;61:1267-72. [DOI: 10.1097/dcr.0000000000001214] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
348 Papp KA, Haraoui B, Kumar D, Marshall JK, Bissonnette R, Bitton A, Bressler B, Gooderham M, Ho V, Jamal S, Pope JE, Steinhart AH, Vinh DC, Wade J. Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies. J Cutan Med Surg 2019;23:50-74. [PMID: 30463418 DOI: 10.1177/1203475418811335] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 12.7] [Reference Citation Analysis]
349 Fiorino G, Allocca M, Chaparro M, Coenen S, Fidalgo C, Younge L, Gisbert JP. 'Quality of Care' Standards in Inflammatory Bowel Disease: A Systematic Review. J Crohns Colitis. 2019;13:127-137. [PMID: 30423033 DOI: 10.1093/ecco-jcc/jjy140] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 9.5] [Reference Citation Analysis]
350 Kim J, Im JP, Yim JJ, Lee CK, Park DI, Eun CS, Jung SA, Shin JE, Lee KM, Cheon JH. Clinical Features and Outcomes of Tuberculosis in Inflammatory Bowel Disease Patients Treated with Anti-tumor Necrosis Factor Therapy. Korean J Gastroenterol 2020;75:29-38. [PMID: 31986571 DOI: 10.4166/kjg.2020.75.1.29] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
351 Ballester Ferré MP, Boscá-Watts MM, Mínguez Pérez M. Crohn's disease. Med Clin (Barc) 2018;151:26-33. [PMID: 29246562 DOI: 10.1016/j.medcli.2017.10.036] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
352 Anushiravani A, Vahedi H, Fakheri H, Mansour-Ghanaei F, Maleki I, Nasseri-Moghaddam S, Vosoghinia H, Ghadir MR, Hormati A, Aminisani N, Radmard AR, Khosravi B, Saberzadeh-Ardestani B, Malekzadeh M, Alatab S, Sadeghi A, Salahi S, Malekzadeh R, Sima AR. A Supporting System for Management of Patients with Inflammatory Bowel Disease during COVID-19 Outbreak: Iranian Experience-Study Protocol. Middle East J Dig Dis 2020;12:238-45. [PMID: 33564380 DOI: 10.34172/mejdd.2020.188] [Reference Citation Analysis]
353 Louis E. Stopping Biologics in IBD-What Is the Evidence? Inflamm Bowel Dis. 2018;24:725-731. [PMID: 29548010 DOI: 10.1093/ibd/izx098] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
354 Spagnuolo R, Larussa T, Iannelli C, Cosco C, Nisticò E, Manduci E, Bruno A, Boccuto L, Abenavoli L, Luzza F, Doldo P. COVID-19 and Inflammatory Bowel Disease: Patient Knowledge and Perceptions in a Single Center Survey. Medicina (Kaunas) 2020;56:E407. [PMID: 32823727 DOI: 10.3390/medicina56080407] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
355 Annese V, Beaugerie L, Egan L, Biancone L, Bolling C, Brandts C, Dierickx D, Dummer R, Fiorino G, Gornet JM, Higgins P, Katsanos KH, Nissen L, Pellino G, Rogler G, Scaldaferri F, Szymanska E, Eliakim R; ECCO. European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. J Crohns Colitis. 2015;9:945-965. [PMID: 26294789 DOI: 10.1093/ecco-jcc/jjv141] [Cited by in Crossref: 189] [Cited by in F6Publishing: 149] [Article Influence: 31.5] [Reference Citation Analysis]
356 Xu F, Carlson SA, Wheaton AG, Greenlund KJ. COVID-19 Hospitalizations Among U.S. Medicare Beneficiaries With Inflammatory Bowel Disease, April 1 to July 31, 2020. Inflamm Bowel Dis 2021;27:1166-9. [PMID: 33904584 DOI: 10.1093/ibd/izab041] [Reference Citation Analysis]
357 Ning L, Liu R, Li S, Shan G, Du H, Zhang J, Chen W, Zhang F, Yu J, Xu G. Increased risk of herpes zoster infection in patients with inflammatory bowel disease: a meta-analysis of cohort studies. Eur J Clin Microbiol Infect Dis 2020;39:219-27. [DOI: 10.1007/s10096-019-03706-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
358 Choi CH, Moon W, Kim YS, Kim ES, Lee B, Jung Y, Yoon YS, Lee H, Park DI, Han DS; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Second Korean Guideline for the Management of Ulcerative Colitis. Korean J Gastroenterol 2017;69:1. [DOI: 10.4166/kjg.2017.69.1.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
359 Chavapradit N, Angkasekwinai N. Disseminated cryptococcosis in Crohn's disease: a case report. BMC Infect Dis 2018;18:620. [PMID: 30514241 DOI: 10.1186/s12879-018-3553-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
360 Irving P, Barrett K, Tang D, Nijher M, de Lusignan S. Common infections, mental health problems and healthcare use in people with inflammatory bowel disease: a cohort study protocol. Evid Based Ment Health 2021;24:82-7. [PMID: 32943436 DOI: 10.1136/ebmental-2020-300167] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
361 Ben Musa R, Gampa A, Basu S, Keshavarzian A, Swanson G, Brown M, Abraham R, Bruninga K, Losurdo J, DeMeo M, Mobarhan S, Shapiro D, Mutlu E. Hepatitis B vaccination in patients with inflammatory bowel disease. World J Gastroenterol. 2014;20:15358-15366. [PMID: 25386085 DOI: 10.3748/wjg.v20.i41.15358] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
362 Ardizzone S, Ferretti F, Monico MC, Carvalhas Gabrielli AM, Carmagnola S, Bezzio C, Saibeni S, Bosani M, Caprioli F, Mazza S, Casini V, Cortelezzi CC, Parravicini M, Cassinotti A, Cosimo P, Indriolo A, Di Sabatino A, Lenti MV, Pastorelli L, Conforti F, Ricci C, Sarzi-Puttini P, Vecchi M, Maconi G. Lower incidence of COVID-19 in patients with inflammatory bowel disease treated with non-gut selective biologic therapy. J Gastroenterol Hepatol 2021. [PMID: 34159648 DOI: 10.1111/jgh.15591] [Reference Citation Analysis]
363 García-Serrano C, Mirada G, Marsal JR, Ortega M, Sol J, Solano R, Artigues EM, Estany P. Compliance with the guidelines on recommended immunization schedule in patients with inflammatory bowel disease: implications on public health policies. BMC Public Health 2020;20:713. [PMID: 32429900 DOI: 10.1186/s12889-020-08850-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
364 Alacam S, Karabulut N, Bakir A, Onel M, Buyuk M, Gulluoglu M, Agacfidan A. Diagnostic significance of cytomegalovirus DNA quantitation in gastrointestinal biopsies: comparison with histopathological data and blood cytomegalovirus DNA. Eur J Gastroenterol Hepatol 2021;33:40-5. [PMID: 32658013 DOI: 10.1097/MEG.0000000000001840] [Reference Citation Analysis]
365 Dragoni G, Bagnoli S, Le Grazie M, Campani C, Rogai F, Manetti N, Bensi C, Macrì G, Galli A, Milla M. Long-term efficacy and safety of vedolizumab in patients with inflammatory bowel diseases: A real-life experience from a tertiary referral center. J Dig Dis 2019;20:235-42. [PMID: 30927309 DOI: 10.1111/1751-2980.12748] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
366 Malhi G, Rumman A, Thanabalan R, Croitoru K, Silverberg MS, Hillary Steinhart A, Nguyen GC. Vaccination in inflammatory bowel disease patients: attitudes, knowledge, and uptake. J Crohns Colitis. 2015;9:439-444. [PMID: 25908717 DOI: 10.1093/ecco-jcc/jjv064] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 7.7] [Reference Citation Analysis]
367 Nakase H, Herfarth H. Cytomegalovirus Colitis, Cytomegalovirus Hepatitis and Systemic Cytomegalovirus Infection: Common Features and Differences. Inflamm Intest Dis 2016;1:15-23. [PMID: 27243020 DOI: 10.1159/000443198] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
368 Bryant RV, Brain O, Travis SP. Conventional drug therapy for inflammatory bowel disease. Scand J Gastroenterol. 2015;50:90-112. [PMID: 25523560 DOI: 10.3109/00365521.2014.968864] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 6.7] [Reference Citation Analysis]
369 Lindhaus C, Tittelbach J, Elsner P. Cutaneous side effects of TNF-alpha inhibitors. J Dtsch Dermatol Ges 2017;15:281-8. [PMID: 28252861 DOI: 10.1111/ddg.13200] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
370 Banaszkiewicz A, Targońska B, Kowalska-Duplaga K, Karolewska-Bochenek K, Sieczkowska A, Gawrońska A, Grzybowska-Chlebowczyk U, Krzesiek E, Łazowska-Przeorek I, Kotowska M, Sienkiewicz E, Walkowiak J, Gregorek H, Radzikowski A, Albrecht P. Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Pediatric Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2015;21:1607-14. [PMID: 25919976 DOI: 10.1097/MIB.0000000000000406] [Cited by in Crossref: 18] [Cited by in F6Publishing: 4] [Article Influence: 3.6] [Reference Citation Analysis]
371 Dignass A, Akbar A, Baumgart DC, Bommelaer G, Bouguen G, Cadiot G, Gillessen A, Grimaud JC, Hart A, Hoque S, Makins R, Michiels C, Moreau J, Premchand P, Ramlow W, Schanz S, Subramanian S, von Tirpitz C, Bonaz B. Granulocyte/monocyte adsorptive apheresis for the treatment of therapy-refractory chronic active ulcerative colitis. Scand J Gastroenterol. 2018;53:442-448. [PMID: 29513111 DOI: 10.1080/00365521.2018.1447598] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
372 Okahara K, Nagata N, Shimada T, Joya A, Hayashida T, Gatanaga H, Oka S, Sakurai T, Uemura N, Akiyama J. Colonic cytomegalovirus detection by mucosal PCR and antiviral therapy in ulcerative colitis. PLoS One 2017;12:e0183951. [PMID: 28886066 DOI: 10.1371/journal.pone.0183951] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
373 Martínez-Gómez X, Curran A, Campins M, Alemany L, Rodrigo-Pendás JÁ, Borruel N, Castellsagué X, Díaz-de-Heredia C, Moraga-Llop FA, Del Pino M, Torné A. Multidisciplinary, evidence-based consensus guidelines for human papillomavirus (HPV) vaccination in high-risk populations, Spain, 2016. Euro Surveill 2019;24. [PMID: 30782268 DOI: 10.2807/1560-7917.ES.2019.24.7.1700857] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 14.0] [Reference Citation Analysis]
374 Yousaf N, Davidson M, Goode E, Thomas C, Hung R, Gore M, Larkin J. The cost of ipilimumab toxicity: a single-centre analysis. Melanoma Research 2015;25:259-64. [DOI: 10.1097/cmr.0000000000000158] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
375 Shrestha MP, Taleban S. Colectomy Rates Are Increasing Among Inpatients With Concomitant Ulcerative Colitis and Clostridioides difficile. Journal of Clinical Gastroenterology 2021;55:709-15. [DOI: 10.1097/mcg.0000000000001412] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
376 Côté-Daigneault J, Peerani F, MacMahon E, Delaporte E, Rahier JF, Colombel JF. Management and Prevention of Herpes Zoster in the Immunocompromised Inflammatory Bowel Disease Patient: A Clinical Quandary. Inflamm Bowel Dis 2016;22:2538-47. [PMID: 27598743 DOI: 10.1097/MIB.0000000000000902] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 4.3] [Reference Citation Analysis]
377 Coccolini F, Improta M, Sartelli M, Rasa K, Sawyer R, Coimbra R, Chiarugi M, Litvin A, Hardcastle T, Forfori F, Vincent JL, Hecker A, Ten Broek R, Bonavina L, Chirica M, Boggi U, Pikoulis E, Di Saverio S, Montravers P, Augustin G, Tartaglia D, Cicuttin E, Cremonini C, Viaggi B, De Simone B, Malbrain M, Shelat VG, Fugazzola P, Ansaloni L, Isik A, Rubio I, Kamal I, Corradi F, Tarasconi A, Gitto S, Podda M, Pikoulis A, Leppaniemi A, Ceresoli M, Romeo O, Moore EE, Demetrashvili Z, Biffl WL, Wani I, Tolonen M, Duane T, Dhingra S, DeAngelis N, Tan E, Abu-Zidan F, Ordonez C, Cui Y, Labricciosa F, Perrone G, Di Marzo F, Peitzman A, Sakakushev B, Sugrue M, Boermeester M, Nunez RM, Gomes CA, Bala M, Kluger Y, Catena F. Acute abdomen in the immunocompromised patient: WSES, SIS-E, WSIS, AAST, and GAIS guidelines. World J Emerg Surg 2021;16:40. [PMID: 34372902 DOI: 10.1186/s13017-021-00380-1] [Reference Citation Analysis]
378 Chaparro M, Gordillo J, Domènech E, Esteve M, Barreiro-de Acosta M, Villoria A, Iglesias-Flores E, Blasi M, Naves JE, Benítez O, Nieto L, Calvet X, García-Sánchez V, Villagrasa JR, Marin AC, Donday MG, Abad-Santos F, Gisbert JP. Fendrix vs Engerix-B for Primo-Vaccination Against Hepatitis B Infection in Patients With Inflammatory Bowel Disease: A Randomized Clinical Trial. Am J Gastroenterol 2020;115:1802-11. [PMID: 33156099 DOI: 10.14309/ajg.0000000000000926] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
379 Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, Kucharzik T, Molnár T, Raine T, Sebastian S, de Sousa HT, Dignass A, Carbonnel F; for the European Crohn’s and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. Journal of Crohn's and Colitis 2017;11:769-84. [DOI: 10.1093/ecco-jcc/jjx009] [Cited by in Crossref: 492] [Cited by in F6Publishing: 373] [Article Influence: 123.0] [Reference Citation Analysis]
380 Piaserico S, Messina F, Russo FP. Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations. Am J Clin Dermatol 2019;20:829-45. [PMID: 31222626 DOI: 10.1007/s40257-019-00457-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
381 Kedia S, Limdi JK, Ahuja V. Management of inflammatory bowel disease in older persons: evolving paradigms. Intest Res 2018;16:194-208. [PMID: 29743832 DOI: 10.5217/ir.2018.16.2.194] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
382 Chang JY, Jung SA, Moon CM, Kim SE, Jung HK, Shim KN. Response to hepatitis B vaccination in patients with inflammatory bowel disease: a prospective observational study in Korea. Intest Res 2018;16:599-608. [PMID: 30301330 DOI: 10.5217/ir.2018.00012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
383 Muhvić-Urek M, Tomac-Stojmenović M, Mijandrušić-Sinčić B. Oral pathology in inflammatory bowel disease. World J Gastroenterol 2016;22:5655-67. [PMID: 27433081 DOI: 10.3748/wjg.v22.i25.5655] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 28] [Article Influence: 10.3] [Reference Citation Analysis]
384 Imperatore N, Castiglione F, Rispo A, Sessa A, Caporaso N, Morisco F. Timing Strategies of Direct-Acting Antivirals and Biologics Administration in HCV-Infected Subjects with Inflammatory Bowel Diseases. Front Pharmacol 2017;8:867. [PMID: 29209223 DOI: 10.3389/fphar.2017.00867] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
385 Fang J, Li W, Peng X, Tan Z, Tan M, Zhang C, Wang W, Xu Z, Zhou G. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving immunosuppressive therapy for glomerulonephritis: a retrospective analysis. Int Urol Nephrol 2017;49:475-82. [PMID: 28032257 DOI: 10.1007/s11255-016-1487-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
386 Sachan A, Srivastava S, Shah J, Singh AK, Mewara A, Vaiphei K, Rana SS. Strongyloides Stercoralis in Acute Severe Ulcerative Colitis-A Triggering Nuisance or An Opportunistic Bystander? Inflamm Bowel Dis 2021:izab119. [PMID: 34019071 DOI: 10.1093/ibd/izab119] [Reference Citation Analysis]
387 Stratton L, Caddy GR. Listeria Rhombencephalitis Complicating Anti-TNF Treatment during an Acute Flare of Crohn's Colitis. Case Rep Gastrointest Med 2016;2016:6216128. [PMID: 27651962 DOI: 10.1155/2016/6216128] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
388 Kucharzik T, Maaser C. Infections and Chronic Inflammatory Bowel Disease. Viszeralmedizin. 2014;30:326-332. [PMID: 26288602 DOI: 10.1159/000366463] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
389 Ludvigsson JF, Sachs MC, Järås J, Malmborg P, Olén O. Serious Infections in Pediatric Inflammatory Bowel Disease 2002-2017-A Nationwide Cohort Study. J Pediatr 2021:S0022-3476(21)00658-2. [PMID: 34216628 DOI: 10.1016/j.jpeds.2021.06.076] [Reference Citation Analysis]
390 Hanada Y, Khanna S, Loftus EV, Raffals LE, Pardi DS. Non– Clostridium difficile Bacterial Infections Are Rare in Patients With Flares of Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology 2018;16:528-33. [DOI: 10.1016/j.cgh.2017.10.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
391 Beaugerie L, Rahier JF, Kirchgesner J. Predicting, Preventing, and Managing Treatment-Related Complications in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2020; 18: 1324-1335. e2. [PMID: 32059920 DOI: 10.1016/j.cgh.2020.02.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 18.0] [Reference Citation Analysis]
392 Su Q, Li X, Mo W, Yang Z. Low serum bilirubin, albumin, and uric acid levels in patients with Crohn's disease. Medicine (Baltimore) 2019;98:e15664. [PMID: 31083269 DOI: 10.1097/MD.0000000000015664] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
393 Al-taweel T, Strohl M, Pai M, Martel M, Bessissow T, Bitton A, Seidman E, Afif W. A Study of Optimal Screening for Latent Tuberculosis in Patients with Inflammatory Bowel Disease. Dig Dis Sci 2018;63:2695-702. [DOI: 10.1007/s10620-018-5178-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
394 Garrido I, Lopes S, Macedo G. Hit the Road JAK! The Role of New Oral Treatment in Inflammatory Bowel Disease. Inflamm Bowel Dis 2021:izab037. [PMID: 33742651 DOI: 10.1093/ibd/izab037] [Reference Citation Analysis]
395 Irving PM, de Lusignan S, Tang D, Nijher M, Barrett K. Risk of common infections in people with inflammatory bowel disease in primary care: a population-based cohort study. BMJ Open Gastroenterol 2021;8:e000573. [PMID: 33597152 DOI: 10.1136/bmjgast-2020-000573] [Reference Citation Analysis]
396 Deepak P, Ludwig DR, Fidler JL, Guglielmo FF, Bruining DH. Medical and Endoscopic Management of Crohn Disease. Top Magn Reson Imaging 2021;30:43-61. [PMID: 33528211 DOI: 10.1097/RMR.0000000000000267] [Reference Citation Analysis]
397 Paul M, Gupta E, Jain P, Rastogi A, Bhatia V. Diagnostic utility of quantitative cytomegalovirus DNA polymerase chain reaction in intestinal biopsies from patients with inflammatory bowel disease. J Lab Physicians 2018;10:38-43. [PMID: 29403203 DOI: 10.4103/JLP.JLP_94_17] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
398 Störkmann H, Rödel J, Stallmach A, Reuken PA. Are CMV-predictive scores in inflammatory bowel disease useful in clinical practice? Z Gastroenterol 2020;58:868-71. [PMID: 32947632 DOI: 10.1055/a-1221-5463] [Reference Citation Analysis]
399 Segal JP, Askari A, Clark SK, Hart AL, Faiz OD. The Incidence and Prevalence of Human Papilloma Virus-associated Cancers in IBD. Inflamm Bowel Dis 2021;27:34-9. [PMID: 32080713 DOI: 10.1093/ibd/izaa035] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
400 Biancone L, Annese V, Ardizzone S, Armuzzi A, Calabrese E, Caprioli F, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D’incà R, Frieri G, Fries W, Gionchetti P, Kohn A, Latella G, Milla M, Orlando A, Papi C, Petruzziello C, Riegler G, Rizzello F, Saibeni S, Scribano ML, Vecchi M, Vernia P, Meucci G, Aratari A, Bossa F, Cappello M, Cassinotti A, Chiriatti A, Fiorino G, Formica V, Guidi L, Losco A, Mocciaro F, Onali S, Pastorelli L, Pica R, Principi M, Renna S, Ricci C, Rispo A, Rogai F, Sarmati L, Scaldaferri F, Spina L, Tambasco R, Testa A, Viscido A. Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease 2017;49:338-58. [DOI: 10.1016/j.dld.2017.01.141] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
401 Cabriada JL, Ruiz-Zorrilla R, Barrio J, Atienza R, Huerta A, Rodríguez-Lago I, Bernal A, Herrero C. Screening for latent tuberculosis infection in patients with inflammatory bowel disease: Can interferon-gamma release assays replace the tuberculin skin test? Turk J Gastroenterol 2018;29:292-8. [PMID: 29755013 DOI: 10.5152/tjg.2018.17162] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
402 Khan N, Trivedi C, Shah Y, Patel D, Lewis J, Yang Y. The Severity of Herpes Zoster in Inflammatory Bowel Disease Patients Treated With Anti-TNF Agents. Inflammatory Bowel Diseases 2018;24:1274-9. [DOI: 10.1093/ibd/izx115] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
403 van Turenhout ST, Berghuis M, Snaebjornsson P, Wilgenhof S, Burgers JA, Haanen JBAG, van Dieren JM. Cytomegalovirus in Steroid-Refractory Immune Checkpoint Inhibition-Related Colitis. J Thorac Oncol 2020;15:e15-20. [PMID: 31864555 DOI: 10.1016/j.jtho.2019.07.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
404 Coenen S, Weyts E, Jorissen C, De Munter P, Noman M, Ballet V, Vermeire S, Van Assche G, Ferrante M. Effects of Education and Information on Vaccination Behavior in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017;23:318-324. [PMID: 28079621 DOI: 10.1097/mib.0000000000001013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 5.7] [Reference Citation Analysis]
405 Ardesia M, Costantino G, Fries W. Lower response to the hepatitis B vaccine in future inflammatory bowel disease patients. Eur J Gastroenterol Hepatol. 2016;28:1101-1102. [PMID: 27465348 DOI: 10.1097/meg.0000000000000670] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
406 Richi P, Alonso O, Martín MD, González-Hombrado L, Navío T, Salido M, Llorente J, Andreu-Vázquez C, García-Fernández C, Jiménez-Diaz A, Lojo L, Cebrián L, Thuissard-Vasallo I, Martínez de Aramayona MJ, Cobo T, García-Castro M, Castro P, Fernández-Castro M, Illera Ó, Steiner M, Muñoz-Fernández S. Evaluation of the immune response to hepatitis B vaccine in patients on biological therapy: results of the RIER cohort study. Clin Rheumatol 2020;39:2751-6. [PMID: 32248433 DOI: 10.1007/s10067-020-05042-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
407 Wei S, Sollano J, Hui YT, Yu W, Santos Estrella PV, Llamado LJQ, Koram N. Epidemiology, burden of disease, and unmet needs in the treatment of ulcerative colitis in Asia. Expert Review of Gastroenterology & Hepatology 2021;15:275-89. [DOI: 10.1080/17474124.2021.1840976] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
408 Zagórowicz E, Przybysz A, Szlak J, Magdziak A, Wieszczy P, Mróz A. Detection of cytomegalovirus by immunohistochemistry of colonic biopsies and quantitative blood polymerase chain reaction: evaluation of agreement in ulcerative colitis. Scand J Gastroenterol 2018;53:435-41. [PMID: 29513050 DOI: 10.1080/00365521.2018.1447596] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
409 Al-Ani AH, Prentice RE, Rentsch CA, Johnson D, Ardalan Z, Heerasing N, Garg M, Campbell S, Sasadeusz J, Macrae FA, Ng SC, Rubin DT, Christensen B. Review article: prevention, diagnosis and management of COVID-19 in the IBD patient. Aliment Pharmacol Ther 2020;52:54-72. [PMID: 32348598 DOI: 10.1111/apt.15779] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 40.0] [Reference Citation Analysis]
410 Yokoyama Y, Yamakawa T, Hirano T, Kazama T, Hirayama D, Wagatsuma K, Nakase H. Current Diagnostic and Therapeutic Approaches to Cytomegalovirus Infections in Ulcerative Colitis Patients Based on Clinical and Basic Research Data. Int J Mol Sci 2020;21:E2438. [PMID: 32244555 DOI: 10.3390/ijms21072438] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
411 Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol. 2017;112:241-258. [PMID: 28071656 DOI: 10.1038/ajg.2016.537] [Cited by in Crossref: 218] [Cited by in F6Publishing: 151] [Article Influence: 54.5] [Reference Citation Analysis]
412 Martínez-Montiel MP, Casis-Herce B, Gómez-Gómez GJ, Masedo-González A, Yela-San Bernardino C, Piedracoba C, Castellano-Tortajada G. Pharmacologic therapy for inflammatory bowel disease refractory to steroids. Clin Exp Gastroenterol 2015;8:257-69. [PMID: 26316792 DOI: 10.2147/CEG.S58152] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
413 Fiorino G, Lytras T, Younge L, Fidalgo C, Coenen S, Chaparro M, Allocca M, Arnott I, Bossuyt P, Burisch J, Campmans-kuijpers M, de Ridder L, Dignass A, Drohan C, Feakins R, Gilardi D, Grosek J, Groß E, Hart A, Jäghult S, Katsanos K, Lönnfors S, Panis Y, Perovic M, Pierik M, Rimola J, Tulchinsky H, Gisbert JP. Quality of Care Standards in Inflammatory Bowel Diseases: a European Crohn’s and Colitis Organisation [ECCO] Position Paper. Journal of Crohn's and Colitis 2020;14:1037-48. [DOI: 10.1093/ecco-jcc/jjaa023] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 20.0] [Reference Citation Analysis]
414 Curtis JR, Regueiro M, Yun H, Su C, DiBonaventura M, Lawendy N, Nduaka CI, Koram N, Cappelleri JC, Chan G, Modesto I, Lichtenstein GR. Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data. Inflamm Bowel Dis 2021;27:1394-408. [PMID: 33324993 DOI: 10.1093/ibd/izaa289] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
415 Kucharzik T, Koletzko S, Kannengiesser K, Dignass A. Ulcerative Colitis-Diagnostic and Therapeutic Algorithms.Dtsch Arztebl Int. 2020;117:564-574. [PMID: 33148393 DOI: 10.3238/arztebl.2020.0564] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
416 Abreu C, Sarmento A, Magro F. Screening, prophylaxis and counselling before the start of biological therapies: A practical approach focused on IBD patients. Dig Liver Dis 2017;49:1289-97. [PMID: 28986117 DOI: 10.1016/j.dld.2017.09.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
417 Pittet LF, Verolet CM, Michetti P, Girardin M, Juillerat P, Mottet C, Maillard MH, Siegrist C, Posfay-barbe KM; the Swiss Inflammatory Bowel Disease Cohort Study Group. High Immunogenicity of the Pneumococcal Conjugated Vaccine in Immunocompromised Adults With Inflammatory Bowel Disease. Am J Gastroenterol 2019;114:1130-41. [DOI: 10.14309/ajg.0000000000000289] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
418 Valdés Delgado T, Cordero Ruiz P, Bellido Muñoz F. Visceral Leishmaniasis Infection in a Patient with Crohn's Disease Treated with Azathioprine. J Crohns Colitis 2017;11:1282-3. [PMID: 28967958 DOI: 10.1093/ecco-jcc/jjx067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
419 Kang EA, Yoon H, Seo AY, Shin CM, Im JP, Park YS, Kim JS, Kim N, Lee DH. Characteristics of cytomegalovirus enterocolitis in patients with or without inflammatory bowel diseases. Scandinavian Journal of Gastroenterology 2018;53:453-8. [DOI: 10.1080/00365521.2018.1450441] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
420 Wright EK, Ding NS, Niewiadomski O. Management of inflammatory bowel disease. Med J Aust 2018;209:318-23. [PMID: 30257634 DOI: 10.5694/mja17.01001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
421 Zhou J, Wu LY, Chen L, Guo YJ, Sun Y, Li T, Zhao JM, Bao CH, Wu HG, Shi Y. Herbs-partitioned moxibustion alleviates aberrant intestinal epithelial cell apoptosis by upregulating A20 expression in a mouse model of Crohn's disease. World J Gastroenterol. 2019;25:2071-2085. [PMID: 31114134 DOI: 10.3748/wjg.v25.i17.2071] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
422 Giugliano FP, Strisciuglio C, Martinelli M, Andreozzi M, Cenni S, Campione S, D’armiento M, Staiano A, Miele E. Does Azathioprine induce endoscopic and histologic healing in pediatric inflammatory bowel disease? A prospective, observational study. Digestive and Liver Disease 2018;50:240-6. [DOI: 10.1016/j.dld.2017.10.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
423 Hakimian S, Popov Y, Rupawala AH, Salomon-Escoto K, Hatch S, Pellish R. The conundrum of indeterminate QuantiFERON-TB Gold results before anti-tumor necrosis factor initiation. Biologics 2018;12:61-7. [PMID: 29520131 DOI: 10.2147/BTT.S150958] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
424 . UEG Week 2018 Poster Presentations. United European Gastroenterol j 2018;6. [DOI: 10.1177/2050640618792819] [Cited by in Crossref: 16] [Article Influence: 5.3] [Reference Citation Analysis]
425 Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, Burisch J, Gecse KB, Hart AL, Hindryckx P. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis. 2017;11:649-670. [PMID: 28158501 DOI: 10.1093/ecco-jcc/jjx008] [Cited by in Crossref: 682] [Cited by in F6Publishing: 512] [Article Influence: 227.3] [Reference Citation Analysis]
426 Guerra I, Algaba A, Jiménez L, Mar Aller M, Garza D, Bonillo D, Molina Esteban LM, Bermejo F. Incidence, Clinical Characteristics, and Evolution of SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: A Single-Center Study in Madrid, Spain. Inflamm Bowel Dis 2021;27:25-33. [PMID: 32830267 DOI: 10.1093/ibd/izaa221] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
427 López-Serrano P, de la Fuente Briongos E, Alonso EC, Pérez-Calle JL, Rodríguez CF. Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy. World J Hepatol. 2015;7:539-547. [PMID: 25848477 DOI: 10.4254/wjh.v7.i3.539] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
428 Park DI, Hisamatsu T, Chen M, Ng SC, Ooi CJ, Wei SC, Banerjee R, Hilmi IN, Jeen YT, Han DS, Kim HJ, Ran Z, Wu K, Qian J, Hu P, Matsuoka K, Andoh A, Suzuki Y, Sugano K, Watanabe M, Hibi T, Puri AS, Yang S. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: Management: AOCC & APAGE consensus on TB in IBD-Part 2. Journal of Gastroenterology and Hepatology 2018;33:30-6. [DOI: 10.1111/jgh.14018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
429 Meredith J, Henderson P, Wilson DC, Van Limbergen J, Wine E, Russell RK. Withdrawal of Combination Immunotherapy in Paediatric Inflammatory Bowel Disease-An International Survey of Practice. J Pediatr Gastroenterol Nutr 2021;73:54-60. [PMID: 33661242 DOI: 10.1097/MPG.0000000000003098] [Reference Citation Analysis]
430 Si XY, Merlin D, Xiao B. Recent advances in orally administered cell-specific nanotherapeutics for inflammatory bowel disease. World J Gastroenterol 2016;22:7718-26. [PMID: 27678353 DOI: 10.3748/wjg.v22.i34.7718] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
431 Caldera F, Saha S, Wald A, Cooley DM, Zhao YQ, Li Z, Bartels CM. Comparing guideline-based care quality for inflammatory bowel disease and rheumatoid arthritis patients within a medical home. Expert Rev Gastroenterol Hepatol 2016;10:759-66. [PMID: 27029237 DOI: 10.1586/17474124.2016.1169920] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
432 Wiedermann U, Sitte HH, Burgmann H, Eser A, Falb P, Holzmann H, Kitchen M, Köller M, Kollaritsch H, Kundi M, Lassmann H, Mutz I, Pickl WF, Riedl E, Sibilia M, Thalhammer F, Tucek B, Zenz W, Zwiauer K. [Guidelines for vaccination of immunocompromised individuals]. Wien Klin Wochenschr 2016;128 Suppl 4:337-76. [PMID: 27457874 DOI: 10.1007/s00508-016-1033-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
433 Macaluso FS, Liguori G, Galli M. Vaccinations in patients with inflammatory bowel disease. Dig Liver Dis 2021:S1590-8658(21)00267-X. [PMID: 34116972 DOI: 10.1016/j.dld.2021.05.015] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
434 Goetgebuer RL, van der Woude CJ, de Ridder L, Doukas M, de Vries AC. Clinical and endoscopic complications of Epstein-Barr virus in inflammatory bowel disease: an illustrative case series. Int J Colorectal Dis 2019;34:923-6. [PMID: 30739187 DOI: 10.1007/s00384-019-03257-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
435 Philip V, Soubieres A, Poullis A. Health concerns associated with travelling with inflammatory bowel disease (IBD): a questionnaire survey. Clin Med (Lond) 2018;18:288-92. [PMID: 30072550 DOI: 10.7861/clinmedicine.18-4-288] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
436 Tran-Minh ML, Sousa P, Maillet M, Allez M, Gornet JM. Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease. World J Hepatol 2017;9:613-26. [PMID: 28539989 DOI: 10.4254/wjh.v9.i13.613] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
437 Horneff G, Seyger MMB, Arikan D, Kalabic J, Anderson JK, Lazar A, Williams DA, Wang C, Tarzynski-Potempa R, Hyams JS. Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease. J Pediatr 2018;201:166-175.e3. [PMID: 30054164 DOI: 10.1016/j.jpeds.2018.05.042] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 7.7] [Reference Citation Analysis]
438 Taxonera C, Ponferrada Á, Riestra S, Bermejo F, Saro C, Martín-arranz MD, Cabriada JL, Barreiro-de Acosta M, de Castro ML, López-serrano P, Barrio J, Suarez C, Iglesias E, Argüelles-arias F, Ferrer I, Marín-jiménez I, Hernández-camba A, Bastida G, Van Domselaar M, Martínez-montiel P, Olivares D, Rivero M, Fernandez-salazar L, Nantes Ó, Merino O, Alba C, Gisbert JP, del Mar Martín-rodriguez M, Botella B, Carpio D, Ceballos D, Verdejo C, Morales I, Legido J, Peñate M, Chaparro M, Algaba A, de Francisco R; CONVERT study group from GETECCU. Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease. Journal of Crohn's and Colitis 2018;12:1270-9. [DOI: 10.1093/ecco-jcc/jjy104] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
439 Sturm A, Maaser C, Mendall M, Karagiannis D, Karatzas P, Ipenburg N, Sebastian S, Rizzello F, Limdi J, Katsanos K, Schmidt C, Jeuring S, Colombo F, Gionchetti P. European Crohn's and Colitis Organisation Topical Review on IBD in the Elderly. J Crohns Colitis 2017;11:263-73. [PMID: 27797918 DOI: 10.1093/ecco-jcc/jjw188] [Cited by in Crossref: 16] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
440 Abreu C, Almeida F, Ferraz R, Dias CC, Sarmento A, Magro F. The tuberculin skin test still matters for the screening of latent Tuberculosis infections among Inflammatory Bowel Disease patients. Digestive and Liver Disease 2016;48:1438-43. [DOI: 10.1016/j.dld.2016.08.107] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
441 Derikx LAAP, Lantinga MA, de Jong DJ, van Dop WA, Creemers RH, Römkens TEH, Jansen JM, Mahmmod N, West RL, Tan ACITL, Bodelier AGL, Gorter MHP, Boekema PJ, Halet ERC, Horjus CS, van Dijk MA, Hirdes MMC, Epping Stippel LSM, Jharap B, Lutgens MWMD, Russel MG, Gilissen LPL, Nauta S, van Bodegraven AA, Hoentjen F. Clinical Outcomes of Covid-19 in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study. J Crohns Colitis 2021;15:529-39. [PMID: 33079178 DOI: 10.1093/ecco-jcc/jjaa215] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
442 Banerjee R, Ali RAR, Wei SC, Adsul S. Biologics for the Management of Inflammatory Bowel Disease: A Review in Tuberculosis-Endemic Countries. Gut Liver 2020;14:685-98. [PMID: 33191310 DOI: 10.5009/gnl19209] [Reference Citation Analysis]
443 Etzion O, Novack V, Perl Y, Abel O, Schwartz D, Munteanu D, Abufreha N, Ben-Yaakov G, Maoz ED, Moshaklo A, Dizingf V, Fich A. Sci-B-VacTM Vs ENGERIX-B Vaccines for Hepatitis B Virus in Patients with Inflammatory Bowel Diseases: A Randomised Controlled Trial. J Crohns Colitis. 2016;10:905-912. [PMID: 26928962 DOI: 10.1093/ecco-jcc/jjw046] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
444 Nuti F, Civitelli F, Cucchiara S. Long-Term Safety of Immunomodulators in Pediatric Inflammatory Diseases. Pediatr Drugs 2014;16:343-52. [DOI: 10.1007/s40272-014-0084-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
445 Xu F, Dahlhamer JM, Terlizzi EP, Wheaton AG, Croft JB. Receipt of Preventive Care Services Among US Adults with Inflammatory Bowel Disease, 2015–2016. Dig Dis Sci 2019;64:1798-808. [DOI: 10.1007/s10620-019-05494-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
446 Barling DR, Tucker S, Varia H, Isaacs P. Large bowel perforation secondary to CMV colitis: an unusual primary presentation of HIV infection. BMJ Case Rep 2016;2016:bcr2016217221. [PMID: 28003231 DOI: 10.1136/bcr-2016-217221] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
447 van Turenhout S, Snaebjornsson P, van Dieren J. Response to "Cytomegalovirus Enterocolitis in a Patient with Refractory Immune-Related Colitis". Case Rep Gastroenterol 2021;15:97-9. [PMID: 33613170 DOI: 10.1159/000511750] [Reference Citation Analysis]
448 Sokol H, Lalande V, Landman C, Bourrier A, Nion-Larmurier I, Rajca S, Kirchgesner J, Seksik P, Cosnes J, Barbut F, Beaugerie L. Clostridium difficile infection in acute flares of inflammatory bowel disease: A prospective study. Dig Liver Dis 2017;49:643-6. [PMID: 28215602 DOI: 10.1016/j.dld.2017.01.162] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
449 Berns M, Hommes DW. Anti-TNF-α therapies for the treatment of Crohn’s disease: the past, present and future. Expert Opinion on Investigational Drugs 2016;25:129-43. [DOI: 10.1517/13543784.2016.1126247] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 7.2] [Reference Citation Analysis]
450 Imperatore N, Foggia M, Patturelli M, Rispo A, Calabrese G, Testa A, Pellegrini L, Tosone G, Di Luna I, Nardone OM, Ricciolino S, Castiglione F. Treatment-based risk stratification of infections in inflammatory bowel disease: A comparison between anti-tumor necrosis factor-α and nonbiological exposure in real-world setting. J Gastroenterol Hepatol 2021;36:1859-68. [PMID: 33283312 DOI: 10.1111/jgh.15367] [Reference Citation Analysis]
451 Li J, Butcher J, Mack D, Stintzi A. Functional Impacts of the Intestinal Microbiome in the Pathogenesis of Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2015;21:139-53. [DOI: 10.1097/mib.0000000000000215] [Cited by in Crossref: 68] [Cited by in F6Publishing: 31] [Article Influence: 11.3] [Reference Citation Analysis]
452 Cohen RD, Bhayat F, Blake A, Travis S. The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data. J Crohns Colitis 2020;14:192-204. [PMID: 31504340 DOI: 10.1093/ecco-jcc/jjz137] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 16.0] [Reference Citation Analysis]
453 Beaugerie L, Carrat F, Nahon S, Zeitoun JD, Sabaté JM, Peyrin-Biroulet L, Colombel JF, Allez M, Fléjou JF, Kirchgesner J, Svrcek M; Cancers et Surrisque Associé aux Maladies Inflammatoires Intestinales En France Study Group. High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn's Disease. Clin Gastroenterol Hepatol 2018;16:892-899.e2. [PMID: 29199142 DOI: 10.1016/j.cgh.2017.11.041] [Cited by in Crossref: 41] [Cited by in F6Publishing: 28] [Article Influence: 10.3] [Reference Citation Analysis]
454 Yang QY, Liu YJ, Xu Y, Zhang L, Wang CD. Monitoring frequency of interferon gamma release assay for tuberculosis surveillance following infliximab therapy in patients with Crohn's disease. J Dig Dis 2021;22:473-80. [PMID: 34240823 DOI: 10.1111/1751-2980.13032] [Reference Citation Analysis]
455 Viazis N, Pontas C, Karmiris K, Dimas I, Fragaki M, Paspatis G, Drygiannakis I, Koutroubakis IE, Moschovis D, Tzouvala M, Theocharis G, Tsolias C, Thomopoulos K, Zampeli E, Axiaris G, Michopoulos S, Belesiotou E, Banasa M, Maraki S, Kouskoumpekou F, Apostolopoulos G, Stamouli V, Prifti H, Mantzaris GJ. Prevalence of Clostridium difficile infection among hospitalized inflammatory bowel disease patients in Greece. Eur J Gastroenterol Hepatol 2019;31:773-6. [PMID: 30973416 DOI: 10.1097/MEG.0000000000001414] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]